
# CITATION REPORT List of articles citing



DOI: 10.1056/nejm200001203420302 New England Journal of Medicine, 2000, 342, 154-60.

Source: https://exaly.com/paper-pdf/31935088/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1726	Clinical trial design and sample size calculation. 356-367		
1725	Dietary Guidelines for Chronic Disease Prevention. <b>2000</b> , 93, 1138-1152		25
1724	Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. <b>2000</b> , 352, 693		16
1723	Reduced concentrations of soluble adhesion molecules after antioxidant supplementation in postmenopausal women with high cardiovascular risk profilesa randomized double-blind study. <b>2000</b> , 94, 227-32		20
1722	Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter?. <i>Circulation</i> , <b>2000</b> , 102, 820-2	16.7	23
1721	AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. <b>2000</b> , 31, 2751-66		189
1720	Bimonthly update: lipidology. Nutrition and metabolism. <b>2000</b> , 11, 551-3		
1719	American Diabetes Association 60th Scientific Sessions, 2000: nutrition, lipids, and alternative medicine. <b>2000</b> , 23, 1847-51		5
1718	Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?. <b>2000</b> , 11, 603-7		38
1717	Roles of endothelial dysfunction in coronary artery disease. <b>2000</b> , 15, 409-15		27
1716	Role of oxidative stress in cardiovascular diseases. <b>2000</b> , 18, 655-73		984
1715	Behavioral Factors Associated with Disease, Injury, and Death among Men: Evidence and Implications for Prevention. <b>2000</b> , 9, 81-142		223
1714	Sense or nonsense?. <b>2000</b> , 102, 322-322		
1713	Drugs used in secondary prevention after myocardial infarction: case presentation. <b>2000</b> , 50, 405-17		3
1712	Why do antioxidants fail to provide clinical benefit?. <b>2000</b> , 1, 38-40		32
1711	F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. <b>2000</b> , 58, 1963-72		77
1710	The Role of Nutrition Therapy in the Management of Diabetes Mellitus. <b>2000</b> , 3, 334-348		

### (2000-2000)

1709 The oxidative modification hypothesis of atherogenesis: an overview. <b>2000</b> , 28, 1815-26		568
Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. <b>2000</b> , 29, 834-45		102
1707 A trawl through the current nutrition literature. <b>2000</b> , 16, 782-4		О
1706 Diffuse coronary artery disease and endothelial dysfunction: form follows function. <b>2000</b> , 9, 19-25		
1705 Role of plaque rupture in acute coronary syndromes. <b>2000</b> , 86, 15J-23J		14
1704 Coronary heart disease: clinical trials review. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 189-93	6	1
1703 Diet and coronary heart disease: clinical trials. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 487-93	6	29
1702 Dietary supplements and cardiovascular disease. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 508-14	6	6
Antioxidants and vitamins to reduce cardiovascular disease. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 342-51	6	24
1700 Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. <b>2000</b> , 2, 293-9		42
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors. <b>2000</b> , 2, 129-31		
Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?. <b>2000</b> , 2, 497-9		2
1697 Vitamin E: cautionary issues. <b>2000</b> , 2, 1-3		2
1696 Vitamin E: Cautionary Issues. <b>2000</b> , 2, 193-196		Ο
1695 Die medikament⊠e Therapie der arteriellen Verschlusskrankheit. <b>2000</b> , 41, 1416-1422		5
1694 The bioavailability bugaboo. <b>2000</b> , 71, 1029-30		11
1693 Vitamin E and Coronary Heart Disease in Tunisians. <b>2000</b> , 46, 1401-1405		13
What role can diet play in the increased risk of cardiovascular disease in women aged 40 years and over?. <b>2000</b> , 173, S101-2		1

1691	Role of angiotensin-converting-enzyme inhibition in patients with renal disease. <b>2000</b> , 57 Suppl 1, S12-8	3	18
1690	Randomized trials or observational tribulations?. New England Journal of Medicine, 2000, 342, 1907-9	59.2	452
1689	Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. <b>2000</b> , 23, 733-8		244
1688	Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 145-53	59.2	6949
1687	The pharmaceutical industryto whom is it accountable?. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1902-4	59.2	111
1686	The HOPE Study (Heart Outcomes Prevention Evaluation). <b>2000</b> , 1, 18-20		74
1685	Increased atherosclerosis in hyperlipidemic mice deficient in alpha -tocopherol transfer protein and vitamin E. <b>2000</b> , 97, 13830-4		200
1684	LiteratureWatch. <b>2000</b> , 6, 239-241		
1683	Protein kinase C activation and its pharmacological inhibition in vascular disease. <b>2000</b> , 5, 173-85		101
1682	C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. <b>2000</b> , 21, 958-60		13
1681	Protective effects of probucol in two animal models of atherosclerosis. <b>2000</b> , 5, 116-8		3
1680	Should the results of the HOPE study affect nephrological practice? For the HOPE investigators. <b>2000</b> , 15, 453-4		4
1679	The acute chest syndrome of sickle cell disease. New England Journal of Medicine, 2000, 342, 1904-7	59.2	87
1678	Vitamin E supplementation and cardiovascular events in high-risk patients. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1917-8	59.2	37
1677	Avoiding Repeat Cardiac Events: The ABCDESs of Tertiary Prevention. 2000, 28, 31-58		4
1676	Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. <b>2000</b> , 31, 2301-6		167
1675	Should physicians prescribe religious activities?. New England Journal of Medicine, 2000, 342, 1913-6	59.2	220
1674	Inter- and intra-individual variation in plasma and red blood cell vitamin E after supplementation. <b>2000</b> , 33, 437-45		52

1673	Therapeutic potential of vitamin E in heart disease. <b>2000</b> , 9, 2629-35	4
1672	Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. <i>Circulation</i> , <b>2000</b> , 102, 539-45	94
1671	The oxidative paradox: another piece in the puzzle. <b>2000</b> , 87, 1074-6	34
1670	Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. <i>Circulation</i> , <b>2000</b> , 102, 1020-6	141
1669	Vitamins C and E protect isolated cardiomyocytes against oxidative damage. <b>2000</b> , 75, 275-81	31
1668	Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein. <b>2000</b> , 49, 1496-500	62
1667	The role of platelets in diabetes-related vascular complications. <b>2000</b> , 50, 1-16	93
1666	Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. <b>2000</b> , 21, 99-166	75
1665	Measurement of lipid-soluble vitaminsfurther adjustment needed?. <b>2000</b> , 355, 2013-4	95
1664	Lancet International Fellowships 2001. <b>2000</b> , 355, 2014	2
1663	Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. <b>2000</b> , 356, 1213-8	845
1662	Model may predict breast cancer recurrence after HDCT. <b>2000</b> , &NA, 18	
1661	Risks of coronary heart disease in women: current understanding and evolving concepts. <b>2000</b> , 75, 1289-303	29
1660	AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. <i>Circulation</i> , <b>2000</b> , 102, 2284-99	1204
1659	Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. <b>2000</b> , 87, 179-83	649
1658	The role of vitamins in the prevention of coronary artery disease. <b>2000</b> , 4, 59-61	2
1657	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. <b>2000</b> , 60, 975-83	32
1656	Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. <b>2000</b> , 36, 758-65	174

1655	HOPE and MICRO-HOPE: review of the results and implications for people with diabetes. 2001, 5, 41-44	1
1654	Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. <b>2001</b> , 30, 983-97	50
1653	Phenol antioxidant quantity and quality in foods: fruits. <b>2001</b> , 49, 5315-21	794
1652	Alpha-tocopherol (vitamin E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial. <b>2001</b> , 157, 167-73	32
1651	The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. <b>2001</b> , 157, 257-83	51
1650	Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. <b>2001</b> , 158, 227-31	71
1649	Effects of a high polyunsaturated fat diet and vitamin E supplementation on high-density lipoprotein oxidation in humans. <b>2001</b> , 159, 459-66	19
1648	Chronic heart failure and micronutrients. <b>2001</b> , 37, 1765-74	182
1647	Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. <b>2001</b> , 38, 1734-40	73
1646	Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking*. <b>2001</b> , 38, 1795-8	18
1645	Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). <b>2001</b> , 38, 1788-94	65
1644	Anti-oxidants a protective role in cardiovascular disease?. <b>2001</b> , 2, 1737-50	28
1643	Antioxidants in health and disease. <b>2001</b> , 54, 176-86	1010
1642	Systematic Reviews of Observational Studies. 211-227	63
1641	Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. <b>2001</b> , 57, 593-601	5
1640	The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. <b>2001</b> , 141, S1-11	21
1639	Terms of reference for Data and Safety Monitoring Committees. <b>2001</b> , 141, 542-7	16
1638	Vitamin E supplementation. <b>2001</b> , 357, 631-2; author reply 632-3	4

### (2001-2001)

Acute effects of oats and vitamin E on endothelial responses to ingested fat. <b>2001</b> , 20, 124-9	33
1636 Insulin resistance and cardiovascular disease. <b>2001</b> , 14, 116S-125S	65
1635 Should we recommend the therapeutical use of vitamin E in diabetic patients?. <b>2001</b> , 10, 159-65	3
On the anti-atherogenic effect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions. <b>2001</b> , 1534, 129-38	10
Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. <b>2001</b> , 306, 1-17	301
1632 Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. <b>2001</b> , 71, 2066-74	26
1631 Atherosclerosis. the road ahead. <b>2001</b> , 104, 503-16	2455
1630 Aspirin for primary prevention of cardiovascular events. <b>2001</b> , 357, 84-5	11
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. <b>2001</b> , 357, 89-95	801
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. <b>2001</b> , 357, 373-80	241
Vitamin E supplementation. <b>2001</b> , 357, 631; author reply 632-3	3
Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. <b>2001</b> , 357, 657-63	435
1625 Antioxidant strategy for cardiovascular disease. <b>2001</b> , 357, 1706	2
1624 Antioxidant strategy for cardiovascular diseases. <b>2001</b> , 357, 1705-6	29
Papel de los antioxidantes en la prevencifi de la enfermedad cardiovascular. <b>2001</b> , 116, 629-635	3
1622 [What is a confounding variable?]. <b>2001</b> , 117, 377-85	7
Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. <b>2001</b> , 76, 619-31	38
1620 [Current topics in vascular biology: an update for the 21st century]. <b>2001</b> , 54, 635-42	О

1619	Novel agents for managing dyslipidaemia. <b>2001</b> , 10, 1901-11		6
1618	Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men. <b>2001</b> , 35, 967-78		39
1617	Opportunities for the treatment of inflammation in cardiovascular disease. <b>2001</b> , 2, 1751-63		1
1616	Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1583-92	59.2	1662
1615	Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. <b>2001</b> , 21, 739-45		128
1614	Clinical practice. What vitamins should I be taking, doctor?. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1819-24	59.2	101
1613	Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation, 2001, 104, 1571-4	16.7	196
1612	Antioxidant vitamin status and carotid atherosclerosis in the elderly. <b>2001</b> , 74, 402-8		69
1611	Does vitamin E decrease heart attack risk? summary and implications with respect to dietary recommendations. <b>2001</b> , 131, 395S-7S		23
1610	The kidney in cardiovascular disease. <b>2001</b> , 134, 707-9		21
1609	Prevention of a first myocardial infarction. <b>2001</b> , 41, 359-67		3
1608	Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. <b>2001</b> , 131, 132-46		87
1607	Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. <b>2001</b> , 73, 1052-7		90
1606	Lipid Peroxidation and Its Inhibition: Overview and Perspectives <b>2001</b> , 50, 313-320		20
1605	Smoking-Induced Vascular Disease. <b>2001</b> , 89, 563-565		13
1604	Analysis, Presentation, and Interpretation of Dietary Data. <b>2001</b> , 69-79		
1603	Enhanced Susceptibility to Oxidation and Diminished Vitamin E Content of LDL from Patients with Stable Coronary Artery Disease. <b>2001</b> , 47, 1234-1240		38
1602	Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. <b>2001</b> , 280, E685-94		748

# (2001-2001)

1601 Vitamin E and atherosclerosis: beyond prevention of LDL oxidation. <b>2001</b> , 131, 366S-8S	40
Improvements in circulating cholesterol, antioxidants, and homocysteine after dietary intervention in an Australian Aboriginal community. <b>2001</b> , 74, 442-8	49
Heme oxygenase as an intrinsic defense system in vascular wall: implication against atherogenesis. <b>2001</b> , 8, 63-70	29
1598 11. References. <b>2001</b> , 175, S84	
1597 Epidemiology of cardiovascular diseases in Europe. <b>2001</b> , 4, 441-57	59
1596 Social inequalities and the burden of food-related ill-health. <b>2001</b> , 4, 1371-3	17
Oral nutritional supplements and heart disease: a review. <b>2001</b> , 8, 255-74	11
1594 Oxidants and antioxidants in atherosclerosis. <b>2001</b> , 12, 411-8	77
Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. <b>2001</b> , 12, 475-84	11
Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of	
coronary heart disease. <b>2001</b> , 12, 395-404	106
	106 4
1592 coronary heart disease. <b>2001</b> , 12, 395-404	,
coronary heart disease. <b>2001</b> , 12, 395-404  1591 Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. <b>2001</b> , 12, 541-6	4
coronary heart disease. <b>2001</b> , 12, 395-404  1591 Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. <b>2001</b> , 12, 541-6  1590 Pleiotropic effects of statins: do they matter?. <b>2001</b> , 12, 391-4	47
coronary heart disease. <b>2001</b> , 12, 395-404  1591 Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. <b>2001</b> , 12, 541-6  1590 Pleiotropic effects of statins: do they matter?. <b>2001</b> , 12, 391-4  1589 Implications from the Heart Outcomes Prevention Evaluation Study. <b>2001</b> , 10, 61-3	47
2001, 12, 395-404  Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. 2001, 12, 541-6  Pleiotropic effects of statins: do they matter?. 2001, 12, 391-4  Implications from the Heart Outcomes Prevention Evaluation Study. 2001, 10, 61-3  The role of plant-based diets in the treatment and prevention of coronary artery disease. 2001, 12, 553	4 47 3-9 4
coronary heart disease. 2001, 12, 395-404  1591 Antioxidants and atherosclerotic cardiovascular disease: unresolved issues. 2001, 12, 541-6  1590 Pleiotropic effects of statins: do they matter?. 2001, 12, 391-4  1589 Implications from the Heart Outcomes Prevention Evaluation Study. 2001, 10, 61-3  1588 The role of plant-based diets in the treatment and prevention of coronary artery disease. 2001, 12, 553  1587 Prognostic implications of endothelial dysfunction: does it mean anything?. 2001, 12, 435-43  The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are	4 47 3-9 4 32

1583 Approches complimentaires. **2001**, 23, 1231-1242

1582	Complementary Approaches. <b>2001</b> , 23, 1204-1213	
1581	Lipoprotein oxidation and atherosclerosis. <b>2001</b> , 29, 358-362	116
1580 (	Guidelines for the management of patients with chronic stable angina: treatment. <b>2001</b> , 135, 616-32	41
1579	The oxidative stress hypothesis of congestive heart failure: radical thoughts. <b>2001</b> , 120, 2035-46	116
1578	Antioxidant supplements to prevent heart disease. Real hope or empty hype?. <b>2001</b> , 109, 109-14	9
1577	Nonhypoglycemic effects of thiazolidinediones. <b>2001</b> , 134, 61-71	304
1576	Is there a vitamin E paradox?. <b>2001</b> , 12, 49-53	36
1575	Therapy and clinical trials. <b>2001</b> , 12, 239-41	
	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. <b>2001</b> , 76, 619-631	64
1573 .	. <b>2001</b> , 3, 945-975	O
1572	Protective nutrients? and up-to-date dietary recommendations. <b>2001</b> , 3, D33-D36	6
	12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice.  Circulation, <b>2001</b> , 104, 1646-50	167
1570	Alpha-tocopherol and atherosclerosis. <b>2001</b> , 226, 5-12	63
1569	Vitamin E and Cardiovascular Disease. <b>2001</b> , 85, 758-760	3
1568	Vitamin E, Atherosclerosis and Thrombosis. <b>2001</b> , 85, 766-770	15
	A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. <b>2001</b> , 73, 219-24	91
1566 \	Vitamin E inhibition of platelet aggregation is independent of antioxidant activity. <b>2001</b> , 131, 374S-7S	51

1565	Dietary modulation of endothelial function: implications for cardiovascular disease. <b>2001</b> , 73, 673-86		264
1564	Current World Literature. 2001, 10, 453-480		
1563	[Drug therapy of arterial hypertension. Results of new intervention studies]. 2001, 42, 1610-8		1
1562	Removal of fat from cow's milk decreases the vitamin E contents of the resulting dairy products. <b>2001</b> , 36, 73-8		15
1561	Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. <b>2001</b> , 36 Suppl, S53-63		122
1560	Prevention of strokes. Current Atherosclerosis Reports, 2001, 3, 321-7	6	5
1559	The renin angiotensin system as a risk factor for coronary artery disease. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 117-24	6	33
1558	Nonesterified fatty acids in blood pressure control and cardiovascular complications. <b>2001</b> , 3, 107-16		36
1557	Antioxidants and endothelial dysfunction in hyperlipidemia. <b>2001</b> , 3, 53-60		50
1556	Lessons learned from prematurely terminated clinical trials. <b>2001</b> , 3, 360-6		2
1555	The impact of herbal medicines on dermatologic surgery. <b>2001</b> , 27, 759-63		59
1554	Primary stroke prevention. <b>2001</b> , 8, 1-15		23
1553	Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. <b>2001</b> , 18, 756-60		85
1552	Multiple role of reactive oxygen species in the arterial wall. <b>2001</b> , 82, 674-82		204
1551	Applications of fatty acid derivatives and antioxidants in dietary lipids. 2001, 103, 42-45		4
1550	n-3 Fatty acids [physiological and technical aspects for their use in food. <b>2001</b> , 103, 45-55		108
1549	Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. <b>2001</b> , 15, 453-8		18
1548	Oxidative stress in cardiovascular disease. <b>2001</b> , 8, 379-89		34

1547	Vitamin E 80th anniversary: a double life, not only fighting radicals. <b>2001</b> , 52, 71-6	25
1546	Comparison of a vitamin E-rich diet and supplemental vitamin E on measures of vitamin E status and lipoprotein profile. <b>2001</b> , 55, 555-61	18
1545	Position of the American Dietetic Association: food fortification and dietary supplements. <b>2001</b> , 101, 115-25	61
1544	A summary of the science supporting the new National Cholesterol Education Program dietary recommendations: what dietitians should know. <b>2001</b> , 101, 1148-54	16
1543	Reductionism and the narrowing nutrition perspective: time for reevaluation and emphasis on food synergy. <b>2001</b> , 101, 1416-9	71
1542	Effect of ingestion of purple grape juice on endothelial function in patients with coronary heart disease. <b>2001</b> , 88, 553-5	112
1541	Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. <b>2001</b> , 89, 187-206	166
1540	Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities. <b>2001</b> , 137, 82-92	1
1539	Antioxidant therapy and atherosclerosis: animal and human studies. <b>2001</b> , 11, 162-5	37
1538	The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. <b>2001</b> , 11, 93-102	307
1537	Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. <b>2001</b> , 31, 1254-62	64
1536	Effect of vitamin E on aortic lipid oxidation and intimal proliferation after arterial injury in cholesterol-fed rabbits. <b>2001</b> , 31, 1245-53	38
1535	Vitamin E and omega-3 fatty acids: effectors of platelet responsiveness. <b>2001</b> , 17, 793-6	21
1534	Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. <b>2001</b> , 7, 265-271	3
1533	Candidate foods in the Asia-Pacific region for cardiovascular protection: relevance of grains and grain-based foods to coronary heart disease. <b>2001</b> , 10, 123-7	
1532	Vitamin E: protective role of a Janus molecule. <b>2001</b> , 15, 2314-25	214
1531	Diet profiles in a population sample from Mediterranean southern France. <b>2001</b> , 4, 173-82	69
1530	Kinins 1925-2000. <b>2001</b> , 382, 3-4	2

#### (2001-2001)

1529	Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. <b>2001</b> , 134, 629-36		962
1528	Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet. <b>2001</b> , 21, 1029-33		56
1527	Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm. <b>2001</b> , 2, 4-10		26
1526	Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. <i>Circulation</i> , <b>2001</b> , 104, 2981-9	16.7	377
1525	New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. <b>2001</b> , 35, 589-617		40
1524	How much is needed for the C-E bounce?. <b>2001</b> , 6, 3-4		
1523	Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. <b>2001</b> , 22, 103-4		22
1522	Patients, families and populations at high risk for coronary heart disease. <b>2001</b> , 22, 1682-90		7
1521	The new US Dietary Reference Intakes for vitamins C and E. <b>2001</b> , 6, 5-9		33
1520	Dietary effects on cardiovascular disease risk factors: beyond saturated fatty acids and cholesterol. <b>2001</b> , 20, 421S-427S; discussion 440S-442S		40
1519	Current approaches to therapy for vascular injury. <b>2001</b> , 2, 753-64		
1518	Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects. <b>2001</b> , 3, 433-49		6
1517	Oxidative stress in chronic renal failure. <b>2001</b> , 16, 2135-7		116
1516	Different isoforms of tocopherols enhance nitric oxide synthase phosphorylation and inhibit human platelet aggregation and lipid peroxidation: implications in therapy with vitamin E. <b>2001</b> , 6, 155-61		36
1515	Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. <i>Circulation</i> , <b>2001</b> , 103, 1863-8	16.7	133
1514	Conundrum of the Brench Paradox[]Circulation, 2001, 103,	16.7	12
1513	Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. <b>2001</b> , 21, 1261-4		83
1512	Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. <b>2001</b> , 21, 365-71		357

1511	Candidate foods in the Asia-Pacific region for cardiovascular protection: relevance of grains and grain-based foods to coronary heart disease. <b>2001</b> , 10, 123-127	2
1510	Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. <i>Circulation</i> , <b>2001</b> , 104, 522-6	157
1509	Comparison of evidence of treatment effects in randomized and nonrandomized studies. <b>2001</b> , 286, 821-30	567
1508	Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function. <i>Circulation</i> , <b>2001</b> , 103, 826-30	50
1507	Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. <b>2001</b> , 21, 585-93	119
1506	Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). <i>Circulation</i> , <b>2001</b> , 103, 919-25	606
1505	Select Vitamins and Minerals in the Management of Diabetes. <b>2001</b> , 14, 133-148	40
1504	Is wine good for your heart? A critical review. <b>2001</b> , 77, 172-6	9
1503	Later management of documented ischaemic heart disease: secondary prevention and rehabilitation. <b>2001</b> , 59, 113-33	5
1502	Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products. <b>2001</b> , 21, E34-7	43
1501	Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. <i>Circulation</i> , <b>2001</b> , 104, 2300-4	91
1500	[Antioxidants in nutrition and arteriosclerosis]. <b>2001</b> , 126, 213-7	2
1499	Antioxidant versus lipid-altering therapysome answers, more questions. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1636-7	16
1498	[Value of complementary medicine exemplified by rose-hips]. <b>2001</b> , 63, 412-6	7
1497	Pharmacological approaches to preserving and restoring coronary endothelial function. <b>2001</b> , 2, 1765-75	1
1496	Any casualties in the clash of randomised and observational evidence?. <b>2001</b> , 322, 879-80	65
1495	Paraoxonase and atherosclerosis. <b>2001</b> , 21, 473-80	627
1494	[Molecular mechanisms of the protective effect of vitamin e against atherosclerosis]. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2002</b> , 80, 662-9	4

1493	Present and future pharmacotherapy for heart failure. <b>2002</b> , 3, 915-30	12
1492	Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. <b>2002</b> , 33, 862-75	166
1491	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <i>Circulation</i> , <b>2002</b> , 105, 1650-5	7 907
1490	Greater oxidative stress in healthy young men compared with premenopausal women. <b>2002</b> , 22, 438-42	226
1489	Antiaging medicine: the good, the bad, and the ugly. <b>2002</b> , 57, M636-9	17
1488	Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. <b>2002</b> , 43, 1618-29	34
1487	Alpha-tocopherol protects against diet induced atherosclerosis in New Zealand white rabbits. <b>2002</b> , 43, 1927-38	25
1486	The 80th anniversary of vitamin E: beyond its antioxidant properties. <b>2002</b> , 383, 457-65	82
1485	Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). <i>Circulation</i> , <b>2002</b> , 16.7, 1453-9	7 256
1484	Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. <b>2002</b> , 25, 1919-27	306
1483	Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. <b>2002</b> , 277, 29116-24	126
1482	Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. <b>2002</b> , 277, 31850-6	104
1481	Statins and vascular protection: a 'radical' view. <b>2002</b> , 20, 359-61	7
1480	VII.5 Microinflammatory state. <b>2002</b> , 17, 100-109	
1479	The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease. <b>2002</b> , 17 Suppl 11, 23-7	34
1478	Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. <b>2002</b> , 162, 1472-6	108
1477	Mixed tocopherols have a stronger inhibitory effect on lipid peroxidation than alpha-tocopherol alone. <b>2002</b> , 39, 714-21	27
1476	Atherogenesisrecent insights into basic mechanisms and their clinical impact. <b>2002</b> , 17, 2055-64	30

1475	Antioxidants and atherosclerosis. <b>2002</b> , 4, B17-B21		12
1474	Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. <b>2002</b> , 20, 1721-4		2
1473	Dietary and adipose tissue gamma-tocopherol and risk of myocardial infarction. <b>2002</b> , 13, 216-23		16
1472	Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. <b>2002</b> , 13, 219-24		15
1471	Effects of intravenous supplementation with alpha-tocopherol in patients receiving total parenteral nutrition containing medium- and long-chain triglycerides. <b>2002</b> , 56, 121-8		27
1470	Dietary antioxidants and cardiovascular disease. <b>2002</b> , 349-376		О
1469	Use of ramipril in preventing stroke: double blind randomised trial. <b>2002</b> , 324, 699-702		286
1468	Serum antioxidant vitamins and blood pressure in the United States population. 2002, 40, 810-6		77
1467	Antioxidant vitamins and lipid therapy: end of a long romance?. <b>2002</b> , 22, 1535-46		64
1466	Vitamin E supplementation and macular degeneration: randomised controlled trial. 2002, 325, 11		109
1465	The hunt for nutritional and pharmacological modulators of paraoxonase. <b>2002</b> , 22, 1248-50		42
1464	Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. <b>2002</b> , 39, 135-41		164
1463	Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. <i>Circulation</i> , <b>2002</b> , 106, 3073-8	6.7	417
1462	Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. <i>Circulation</i> , <b>2002</b> , 106, 2543-9	6.7	102
1461	Cardiovascular aging is associated with vitamin E increase. <i>Circulation</i> , <b>2002</b> , 105, 1635-8	6.7	38
1460	Antioxidants: bridging the gap between biochemistry and clinical practice. 2002, 17, 3-4		1
1459	Current World Literature. 2002, 13, 421-435		
1458	Current world literature. 2002, 15, 263-82		

1457 Preventive management of stroke. **2002**, 1415-1428

1456 Prevention of plaque rupture: a new paradigm of therapy. <b>2002</b> , 137, 823-33		31
Nutri <b>B</b> e exerc <b>B</b> io na preven <b>B</b> e controle das doen <b>B</b> s cardiovasculares. <b>2002</b> , 8, 244-254		32
1454 Dietary prevention of sudden cardiac death. <b>2002</b> , 23, 277-85		17
Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. <b>2002</b> , 16, 68-85		100
1452 The Heart Protection Study: death knell for the oxidation theory of atherosclerosis?. <b>2002</b> , 13, 355		
Vascular oxidative stress and antioxidant protection in atherosclerosis: what do the clinical trials say?. <b>2002</b> , 22, 225-33		6
Dietary modulations in the prevention of coronary artery disease: a special emphasis on vitamins and fish oil. <b>2002</b> , 17, 559-67		6
1449 Complementary Approaches. <b>2002</b> , 24, 74-83		
1448 Vitamins. <b>2002</b> , 34-96		1
1447 Lipoproteins, nutrition, and heart disease. <b>2002</b> , 75, 191-212		279
1446 The European perspective on vitamin E: current knowledge and future research. <b>2002</b> , 76, 703-16		435
Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. <b>2002</b> , 76, 549-55		140
1444 THE USE OF COMPLEMENTARY AND ALTERNATIVE THERAPIES IN DIABETES. <b>2002</b> , 4, 911-928		2
Mediterranean diet and prevention of coronary heart disease. <b>2002</b> , 25, 296-9		8
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. <b>2002</b> , 25, 148-98		527
1441 Is there an antiaging medicine?. <b>2002</b> , 57, B333-8		30
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update:  Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and	16.7	1349

1439	Lower is better: The Heart Protection Study. <b>2002</b> , 5, 166-7	1
1438	Premature termination of clinical trialslessons learned. <b>2002</b> , 4, 219-25	4
1437	Effect of long-term therapy with ramipril in high-risk women. <b>2002</b> , 40, 693-702	46
1436	Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. <b>2002</b> , 161, 307-16	123
1435	Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits. <b>2002</b> , 162, 111-7	16
1434	The use of antioxidant supplements in coronary heart disease. <b>2002</b> , 164, 211-9	97
1433	Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. <b>2002</b> , 165, 277-83	126
1432	Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. <b>2002</b> , 41, 207-24	79
1431	Ramipril: a review of its use in the prevention of cardiovascular outcomes. <b>2002</b> , 62, 1381-405	43
1430	The biochemistry of antioxidants revisited. <b>2002</b> , 17, 5-17	32
1429	Molecular understanding of hyperglycemia's adverse effects for diabetic complications. <b>2002</b> , 288, 2579-88	670
1428	Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. <b>2002</b> , 19, 793-805	25
1427	Vitamin E and prostate cancer. <b>2002</b> , 29, 107-13, ix	25
1426	Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. <i>Circulation</i> , <b>2002</b> , 106, 2775-80	63
1425	Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. <b>2002</b> , 40, 804-9	156
1424	Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. <b>2002</b> , 2, 15-21	25
1423	Naturoceutical agents in the management of cardiovascular disease. <b>2002</b> , 2, 173-96	18
1422	Prevention of restenosis with antioxidants: mechanisms and implications. <b>2002</b> , 2, 323-34	48

1421	Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?. <b>2002</b> , 59, 9-19	62
1420	Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. <b>2002</b> , 59, 20-33	111
1419	Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. <b>2002</b> , 359, 1108-13	265
1418	Blood pressure and cardiovascular risk in the HOPE study. <b>2002</b> , 359, 2118	2
1417	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. <b>2002</b> , 360, 23-33	1218
1416	Two decades of progress in preventing vascular disease. <b>2002</b> , 360, 2-3	281
1415	Diet and risk of coronary heart disease and type 2 diabetes. <b>2002</b> , 360, 783-9	177
1414	Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. <b>2002</b> , 359, 1969-74	367
1413	Prolonged, low dose alpha-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation. <b>2002</b> , 320, 5-9	11
1412	Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. <i>Circulation</i> , <b>2002</b> , 105, 2107-11	396
		396
1411	trials conducted to date refute the hypothesis?. <i>Circulation</i> , <b>2002</b> , 105, 2107-11	
1411	trials conducted to date refute the hypothesis?. <i>Circulation</i> , <b>2002</b> , 105, 2107-11  Evaluation of interventions. <b>2002</b> , 55, 1183-90	13
1411 1410 1409	Evaluation of interventions. 2002, 55, 1183-90  C-reactive protein: history and revival. 2002, 13, 412	13
1411 1410 1409	trials conducted to date refute the hypothesis?. <i>Circulation</i> , <b>2002</b> , 105, 2107-11  Evaluation of interventions. <b>2002</b> , 55, 1183-90  C-reactive protein: history and revival. <b>2002</b> , 13, 412  Effect of mixed tocopherols on ecNOS, SOD and PKC in leukocytes in human subjects. <b>2002</b> , 22, 1253-1263	13 112 5
1411 1410 1409 1408	Evaluation of interventions. 2002, 55, 1183-90  C-reactive protein: history and revival. 2002, 13, 412  Effect of mixed tocopherols on ecNOS, SOD and PKC in leukocytes in human subjects. 2002, 22, 1253-1263  Cardiovascular disease. 2002, 29, 323-38, vi	13 112 5 8
1411 1410 1409 1408 1407	Evaluation of interventions. 2002, 55, 1183-90  C-reactive protein: history and revival. 2002, 13, 412  Effect of mixed tocopherols on ecNOS, SOD and PKC in leukocytes in human subjects. 2002, 22, 1253-1263  Cardiovascular disease. 2002, 29, 323-38, vi  [Alcohol and the heart, two sides of the same coin]. 2002, 118, 696-7	13 112 5 8

1403	Cardiovascular disease prevention. <b>2002</b> , 29, 667-96	3
1402	Prevention of Type 2 Diabetes. 75-176	4
1401	Effect of Ramipril and Vitamin E on Atherosclerosis. <i>Circulation</i> , <b>2002</b> , 105,	
1400	Dietary and circulating antioxidant vitamins in relation to carotid plaques in middle-aged women. <b>2002</b> , 76, 582-7	35
1399	The Current View on Hypercholesterolemia after the Heart Protection StudyIIDo We Need New Strategies?. <b>2002</b> , 2, 201-203	
1398	Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. <b>2002</b> , 17, 174-85	15
1397	Women's angiographic vitamin and estrogen trial: design and methods. <b>2002</b> , 23, 708-27	19
1396	New horizons for stroke prevention: PROGRESS and HOPE. <b>2002</b> , 1, 149-56	55
1395	Discrepancies in nutritional recommendations: the need for evidence based nutrition. <b>2002</b> , 11 Suppl 3, S510-5	12
1394	An update: vitamin E supplementation and heart disease. <b>2002</b> , 5, 50-5	10
1393	Relationship of serum antioxidant vitamins to serum creatinine in the US population. <b>2002</b> , 39, 460-8	21
1392	Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. <b>2002</b> , 32, 1090-101	92
1391	Serum protein acrolein adducts: utility in detecting oxidant stress in hemodialysis patients and reversal using a vitamin E-bonded hemodialyzer. <b>2002</b> , 33, 1651-6	30
1390	Miscellaneous medications for the management of atherosclerosis: Mayhem or miracle?. <b>2002</b> , 15, 275-287	
1389	Nutrition and disease: challenges of research design. <b>2002</b> , 18, 343-7	15
1388	Lipoprotein oxidation and its significance for atherosclerosis: a mathematical approach. 2002, 64, 65-95	66
1387	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. <b>2002</b> , 18 Suppl 3, S82-5	55
1386	Atherosclerotic Risk Factors in Patients with Ischemic Cerebrovascular Disease. <b>2002</b> , 4, 445-453	9

Cardiac and vascular structure and function are related to lipid peroxidation and metabolism. <b>2002</b> , 37, 231-6	36	
Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. <i>Current Atherosclerosis Reports</i> , <b>2002</b> , 4, 373-80	33	
1383 Antioxidant vitamins and their influence in diabetes mellitus. <b>2002</b> , 2, 448-56	49	,
1382 [Antioxidant therapy in vascular and renal diseases]. <b>2002</b> , 97, 144-51	5	
1381 Carotenoids: separation methods applicable to biological samples. <b>2002</b> , 781, 393-418	80	)
1380 Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. <b>2002</b> , 251, 372-92	16.	4
1379 Plasma vitamin E, total antioxidant status and vascular function in young adults. <b>2002</b> , 32, 889-94	6	
Long-term vitamin E supplementation fails to reduce lipid peroxidation in people at cardiovascular risk: analysis of underlying factors. <b>2002</b> , 3, 5	10	
Roles of oxidized low-density lipoprotein and its receptors in the pathogenesis of atherosclerotic diseases. <b>2002</b> , 2, 172-178	1	
Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. <b>2002</b> , 16, 411-5	79	
Combined vitamin C and E supplementation retards early progression of arteriosclerosis in heart transplant patients. <b>2002</b> , 60, 368-71	70	)
1374 Effect of vitamin E on glutathione-dependent enzymes. <b>2003</b> , 35, 215-53	45	
1373 Prevention of Cardiovascular Disease in Women. <b>2003</b> , 5, 287-298		
1372 Efficacy of over-the-counter nutritional supplements. <i>Current Atherosclerosis Reports</i> , <b>2003</b> , 5, 15-21 6	9	
Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low-density lipoprotein oxidation hypothesis?. <i>Current Atherosclerosis Reports</i> , <b>2003</b> , 5, 83-7	18	
1370 Oxidative stress and heart disease: cardiac dysfunction, nutrition, and gene therapy. <b>2003</b> , 5, 215-20	18	
Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. <b>2003</b> , 28, 628-38	82	
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002part I]. <b>2003</b> , 98, 218-25	1	

Konservative Therapie und SekundEprNention der peripheren arteriellen Verschlusskrankheit im Stadium der Claudicatio intermittens. **2003**, 8, S46-S52

1366	Beyond LDL oxidation: ROS in vascular signal transduction. <b>2003</b> , 35, 117-32	130
1365	REFERENCES. <b>2003</b> , 41, S77-S91	
1364	Carvedilol improves energy production during acute global myocardial ischaemia. <b>2003</b> , 482, 245-53	13
1363	Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. <b>2003</b> , 91, 12A-16A	120
1362	Clinical results with AGI-1067: a novel antioxidant vascular protectant. <b>2003</b> , 91, 41A-49A	30
1361	Prognostic value of endothelial function. <b>2003</b> , 91, 19H-24H	127
1360	Role of endothelial dysfunction in insulin resistance. <b>2003</b> , 92, 10J-17J	193
1359	The evolution of the randomized controlled trial and its role in evidence-based decision making. <b>2003</b> , 254, 105-13	109
1358	Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. <b>2003</b> , S33-8	53
1357	Uremia-related metabolic cardiac risk factors in chronic kidney disease. <b>2003</b> , 16, 148-56	30
1356	A high-score Mediterranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with Type 2 diabetes. <b>2003</b> , 1, 1744-52	75
1355	Pathophysiological implications of insulin resistance on vascular endothelial function. <b>2003</b> , 20, 255-68	198
1354	Nitrate tolerance and the links with endothelial dysfunction and oxidative stress. 2003, 56, 620-8	18
1353	Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. 2003, 11, 112-20	39
1352	Oxidative stress status in patients with diabetes mellitus: relationship to diet. <b>2003</b> , 57, 999-1008	65
1351	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. <b>2003</b> , 10, 420-428	14
1350	[Paraoxonase, something more than an enzyme?]. 2003, 121, 537-48	56

1349	In the statin era, how important are intense lifestyle changes?. <b>2003</b> , 41, 273-4	3
1348	Antioxidants, statins, and atherosclerosis. <b>2003</b> , 41, 1205-10	56
1347	Effect of supplemental phytonutrients on impairment of the flow-mediated brachial artery vasoactivity after a single high-fat meal. <b>2003</b> , 41, 1744-9	72
1346	High-fat diets and cardiovascular disease: are nutritional supplements useful?. 2003, 41, 1750-2	14
1345	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <b>2003</b> , 10, S1-S78	44
1344	Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. <b>2003</b> , 42, 437-59	116
1343	Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. <i>Circulation</i> , <b>2003</b> , 107, 2775-9	350
1342	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure 16.7 Research, Clinical Cardiology, and Epidemiology and Prevention. <i>Circulation</i> , <b>2003</b> , 108, 2154-69	2515
1341	Oxidative stress in cardiovascular disease: myth or fact?. <b>2003</b> , 420, 217-21	124
1340	Extent of copper LDL oxidation depends on oxidation time and copper/LDL ratio: chemical characterization. <b>2003</b> , 420, 68-78	21
1339	Endothelial dysfunction: clinical strategies for treating oxidant stress. <b>2003</b> , 146, 218-26	64
1338	Tomatoes and cardiovascular health. <b>2003</b> , 43, 1-18	274
1337	Treatment of atherosclerosis in the new millennium: is there a role for vitamin E?. 2003, 6, 85-90	16
1336	ASAP and ANTIBIO. <b>2003</b> , 6, 166-8	
1335	What should we advise our patients about taking antioxidants?. <b>2003</b> , 5, 231-3	1
1334	The role of plasma thiol compounds and antioxidant vitamins in patients with cardiovascular diseases. <b>2003</b> , 338, 99-105	42
1333	The clinical implications of endothelial dysfunction. <b>2003</b> , 42, 1149-60	1219
1332	Antioxidant supplement use in Women's Health Initiative participants. <b>2003</b> , 36, 379-87	27

1331	Human requirements for fat-soluble vitamins, and other things concerning these nutrients. <b>2003</b> , 24, 317-24	7
1330	Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. <b>2003</b> , 361, 2017-23	852
1329	The role of omega-3 fatty acids in cardiovascular disease. <i>Current Atherosclerosis Reports</i> , <b>2003</b> , 5, 139-4 <b>%</b>	74
1328	Diabetes mellitus, oxidative stress and endothelial dysfunction. <b>2003</b> , 1253, 125-138	4
1327	Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. <b>2003</b> , 60, 12-25	3
1326	The role of vitamin E in atherosclerosis. <b>2003</b> , 42, 405-22	100
1325	Reactive oxygen species in vascular biology: role in arterial hypertension. <b>2003</b> , 1, 91-106	117
1324	Oxidative stress and cardiovascular injury: Part II: animal and human studies. <i>Circulation</i> , <b>2003</b> , 108, 2034: 607	631
1323	HRT and/or vitamins did not prevent the progression of coronary artery disease in postmenopausal women. <b>2003</b> , 5, 98-99	
1322	Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. <b>2003</b> , 52, 1-8	1139
1322		1139
	dysfunction?. <b>2003</b> , 52, 1-8	
1321	dysfunction?. 2003, 52, 1-8  The antioxidantsvitamin C,vitamin E, selenium, and carotenoids. 2003, 9, 65-82  Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. 2003	41
1321 1320 1319	dysfunction?. 2003, 52, 1-8  The antioxidantsvitamin C,vitamin E, selenium, and carotenoids. 2003, 9, 65-82  Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. 2003, 2, 293-304  Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human	41 35
1321 1320 1319	The antioxidantsvitamin C,vitamin E, selenium, and carotenoids. 2003, 9, 65-82  Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. 2003, 2, 293-304  Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. 2003, 37, 1235-44	41 35 20
1321 1320 1319	The antioxidantsvitamin C,vitamin E, selenium, and carotenoids. 2003, 9, 65-82  Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. 2003, 2, 293-304  Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. 2003, 37, 1235-44  Vitamin E: the evidence for multiple roles in cancer. 2003, 46, 1-14  Endothelium, inflammation, and diabetes. 2003, 1, 3-21	41 35 20 26
1321 1320 1319 1318	The antioxidantsvitamin C,vitamin E, selenium, and carotenoids. 2003, 9, 65-82  Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. 2003, 2, 293-304  Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. 2003, 37, 1235-44  Vitamin E: the evidence for multiple roles in cancer. 2003, 46, 1-14  Endothelium, inflammation, and diabetes. 2003, 1, 3-21	41 35 20 26

1313	Clinical utility of endothelial function testing: ready for prime time?. Circulation, 2003, 107, 3243-7	16.7	128
1312	Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. <b>2003</b> , 44, 800-6		61
1311	Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. <b>2003</b> , 23, 1601-7		86
1310	Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. <b>2003</b> , 14, 641-7		110
1309	Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of US male physicians. <i>Circulation</i> , <b>2003</b> , 108, 802-7	16.7	76
1308	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. <b>2003</b> , 42, 1050-65		802
1307	Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. <b>2003</b> , 26, 3264-72		328
1306	Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. <b>2003</b> , 92, 1193-200		207
1305	Biofactors in the Mediterranean diet. <b>2003</b> , 41, 999-1004		21
1304	Is oxidant stress a connection between obesity and atherosclerosis?. <b>2003</b> , 23, 368-70		75
1304	Is oxidant stress a connection between obesity and atherosclerosis?. 2003, 23, 368-70  Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2003, 107, 251-7	16.7	75 119
	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention	16.7	
1303	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7  Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation.	16.7	119
1303	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7  Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. <b>2003</b> , 22, 400-7  NADPH oxidase in endothelial cells: impact on atherosclerosis. <b>2003</b> , 5, 171-80	16.7	119 26
1303 1302 1301	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7  Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. <b>2003</b> , 22, 400-7  NADPH oxidase in endothelial cells: impact on atherosclerosis. <b>2003</b> , 5, 171-80	16.7	<ul><li>119</li><li>26</li><li>75</li></ul>
1303 1302 1301	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7  Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. <b>2003</b> , 22, 400-7  NADPH oxidase in endothelial cells: impact on atherosclerosis. <b>2003</b> , 5, 171-80  Does vitamin E supplementation prevent cardiovascular events?. <b>2003</b> , 12, 123-36  Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. <i>Circulation</i> , <b>2003</b> , 108, 24-31		<ul><li>119</li><li>26</li><li>75</li><li>14</li></ul>
1303 1302 1301 1300	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7  Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. <b>2003</b> , 22, 400-7  NADPH oxidase in endothelial cells: impact on atherosclerosis. <b>2003</b> , 5, 171-80  Does vitamin E supplementation prevent cardiovascular events?. <b>2003</b> , 12, 123-36  Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. <i>Circulation</i> , <b>2003</b> , 108, 24-31		<ul><li>119</li><li>26</li><li>75</li><li>14</li></ul>

1295	Antioxidants and atherosclerosis: don't throw out the baby with the bath water. <i>Circulation</i> , <b>2003</b> , 107, 926-8	150
1294	Mechanisms of oxidative stress and vascular dysfunction. <b>2003</b> , 79, 195-199; quiz 198-200	119
1293	Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. <b>2003</b> , 18, 2415-20	68
1292	Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. <b>2003</b> , 285, H2392-8	113
1291	Nutritional composition of selected wild plants in the diet of Crete. <b>2003</b> , 91, 22-40	42
1290	Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. <b>2003</b> , 57, 604-11	168
1289	Treatment of arteriosclerosis. 2003, 128, 41-7	3
1288	Oxidative stress, the renin-angiotensin system, and atherosclerosis. <b>2003</b> , 5, A3-A7	19
1287	Oxygen Free Radicals in Heart Disease. <b>2003</b> , 47-66	2
1286	. <b>2003</b> , 14, 493-497	
1285	Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. <b>2003</b> , 163, 33-40	114
1284	Oxygen free radicals and the disease process. <b>2003</b> , 28, 53-4	3
1283	Oxidative stress and heart failure. <b>2003</b> , 14, 109-13	33
1282	Development of an NP role in interventional radiology. <b>2003</b> , 28, 57-8	3
1281	Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. <b>2003</b> , 14, 353-9	112
1280	Diabetes mellitus and endothelial dysfunction: a central role for oxidative stress. <b>2003</b> , 10, 237-244	3
1279	Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies. <b>2003</b> , 5, B51-B57	7
1278	Analysis and reporting of factorial trials: a systematic review. <b>2003</b> , 289, 2545-53	190

1277	Has the time come to use antioxidant therapy in uraemic patients?. <b>2003</b> , 18, 1452-5	9
1276	A new treatment for morbid obesity. <b>2003</b> , 28, 54-5	
1275	Effects of phenolics on vascular endothelial function. <b>2003</b> , 14, 21-7	38
1274	Cataract extraction and cognitive function in older women. <b>2003</b> , 14, 493-7	35
1273	Practice powder-free and latex safe. <b>2003</b> , 28, 55-7	
1272	Food-based approaches to prevent and control micronutrient malnutrition: scientific evidence and policy implications. <b>2003</b> , 91, 76-131	8
1271	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. <b>2003</b> , 10, 420-8	32
1270	Overview: Membrane lipid peroxidation. <b>2003</b> , 12, 11-26	2
1269	Cardiology Grand Rounds from the University of North Carolina at Chapel Hill. The antioxidant vitamins and coronary heart disease: Part II. Randomized clinical trials. <b>2003</b> , 325, 15-9	4
1268	Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. <b>2003</b> , 139, 51-5	60
1267	Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. <b>2003</b> , 139, 56-70	147
1266	Inflammation in uremic patients: what is the link?. <b>2003</b> , 26, 65-75	11
1265	Dietary lycopene, tomato-based food products and cardiovascular disease in women. <b>2003</b> , 133, 2336-41	173
1264	Extended Abstracts. <b>2003</b> , 21, 327-349	
1263	Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. <b>2003</b> , 89, 990-995	49
1262	Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. 2003, 77, 700-6	104
1261	Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. <b>2003</b> , 133, 3137-40	133
1260	Dietary Supplements for Geriatric Patients. <b>2003</b> , 921-929	

1259	Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. <b>2003</b> , 285, C723-34	101
1258	Treatment of hypertension in peripheral arterial disease. <b>2003</b> , CD003075	12
1257	Multivitamin supplements are inversely associated with risk of myocardial infarction in men and women–Stockholm Heart Epidemiology Program (SHEEP). <b>2003</b> , 133, 2650-4	41
1256	Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. <b>2003</b> , 285, H822-32	69
1255	Monocyte chemoattractant protein-1 involvement in the alpha-tocopherol-induced reduction of atherosclerotic lesions in apolipoprotein E knockout mice. <b>2003</b> , 90, 3-11	15
1254	American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. <b>2003</b> , 9, 417-70	56
1253	[How do blood vessels age? Mechanisms and clinical implications]. 2004, 33, 3-11	11
1252	Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. <b>2004</b> , 25, 1171-8	82
1251	Handbook of Clinical Nutrition and Aging. <b>2004</b> ,	4
1250	[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?]. <b>2004</b> , 129, 321-6	2
1249	Diet and the prevention of coronary heart disease. <b>2004</b> , 21-55	0
1248	Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. <b>2004</b> , 2, 155-9	3
1247	Role of beta2-glycoprotein I, LDL-, and antioxidant levels in hypercholesterolemic elderly subjects. <b>2004</b> , 6, 237-44	27
1246	The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. <b>2004</b> , 13, 99-117	41
1245	Nutrition and physical activity and chronic disease prevention: research strategies and recommendations. <b>2004</b> , 96, 1276-87	75
1244	Effect of chronic oral supplementation with vitamins on the endothelial function in chronic smokers. <b>2004</b> , 55, 653-60	14
1243	A case-control study of serum tocopherol levels and the alpha- to gamma-tocopherol ratio in radiographic knee osteoarthritis: the Johnston County Osteoarthritis Project. <b>2004</b> , 159, 968-77	39
1242	Endothelial function and oxidative stress. <b>2004</b> , 11, 123-32	119

1241	Dietary lipids and vascular function: UK Food Standards Agency workshop report. <b>2004</b> , 91, 491-500		23
1240	Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. <i>Circulation</i> , <b>2004</b> , 109, 2109-15	16.7	107
1239	Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. <b>2004</b> , 164, 1552-6		165
1238	Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. <i>Circulation</i> , <b>2004</b> , 110, 1413-7	16.7	46
1237	Micronutrient supplementation in later life: limited evidence for benefit. <b>2004</b> , 59, 659-73		28
1236	Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). <b>2004</b> , 24, 498-503		83
1235	Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. <b>2004</b> , 160, 1223-33		280
1234	Scaffolds direct Src-specific signaling in response to angiotensin II: new roles for Cas and GIT1. <b>2004</b> , 65, 822-5		13
1233	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. <b>2004</b> , 29, 5-54		
1232	Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. 2004, 44, 381-	5	237
1231	Surrogate markers for cardiovascular disease: functional markers. <i>Circulation</i> , <b>2004</b> , 109, IV31-46	16.7	167
1230	Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. <b>2004</b> , 17, 59-67		317
1229	A Commentary on Treatment at Random: The Ultimate Science or the Betrayal of Hippocrates?. <b>2004</b> , 22, 5009-5011		10
1228	Vitamin E is not deficient in human atherosclerotic plaques. <b>2004</b> , 24, e139-40; author reply e141-2		3
1227	Atherogenic lipoprotein particles in atherosclerosis. Circulation, 2004, 109, III2-7	16.7	258
1226	Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. <b>2004</b> , 35, 1908-13		18
1225	The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. <b>2004</b> , 27, 925-30		41
	A review of the epidemiological evidence for the 'antioxidant hypothesis'. <b>2004</b> , 7, 407-22		327

1223	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. <b>2004</b> , 27, 2767	70
1222	Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. <i>Circulation</i> , <b>2004</b> , 109, 2617-25	245
1221	Oxidative stress during myocardial ischaemia and heart failure. <b>2004</b> , 10, 1699-711	152
1220	Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. <b>2004</b> , 97, 537-48	96
1219	The relationship between antioxidant supplements and oxidative stress in renal transplant recipients: a review. <b>2004</b> , 50, 451-7	10
1218	Consequences of diabetes: cardiovascular disease. <b>2004</b> , 27, 1825-31	18
1217	Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. <b>2004</b> , 53, 2633-9	28
1216	Oxidative stress in hypertension. <b>2004</b> , 26, 593-601	145
1215	Principles of Diabetes Mellitus. <b>2004</b> ,	
1214	Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation. <b>2004</b> , 286, G437-43	15
1213	Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. <b>2004</b> , 24, 1485-91	121
1212	Evidence-based guidelines for cardiovascular disease prevention in women. <i>Circulation</i> , <b>2004</b> , 109, 672-9 <b>3</b> 6.7	526
1211	Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. <b>2004</b> , 286, F606-16	199
1210	Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. <b>2004</b> , 24, e29-50	55
1209	An ideal ocular nutritional supplement?. <b>2004</b> , 24, 339-49	38
1208	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. <b>2004</b> , 65, 1375-80	84
1207	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. <b>2004</b> , S59-62	56
1206	Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. <b>2004</b> , 19, 380-9	121

1205	Antioxidant therapy in uremia: evidence-based medicine?. <b>2004</b> , 17, 327-32	13
1204	Anti-atherosclerotic effects of vitamin Emyth or reality?. <b>2004</b> , 8, 59-76	111
1203	Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities. <b>2004</b> , 143, 99-105	6
1202	Vitamin C pharmacokinetics of plain and slow release formulations in smokers. <i>Clinical Nutrition</i> , <b>2004</b> , 23, 1043-50	18
1201	New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. <b>2004</b> , 36, 1-15	233
1200	Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid. <b>2004</b> , 36, 123-30	8
1199	Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. <b>2004</b> , 36, 959-65	31
1198	In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. <b>2004</b> , 56, 615-20	35
1197	Antioxidant and oxidative stress changes in experimental cor pulmonale. <b>2004</b> , 260, 21-9	57
1196	Vitamin E and cardiovascular disease: observational studies. <b>2004</b> , 1031, 280-91	44
1195	Vitamin E for the treatment of cardiovascular disease: is there a future?. <b>2004</b> , 1031, 292-304	24
1194	Reactive oxygen species in vascular biology: implications in hypertension. <b>2004</b> , 122, 339-52	482
1193	The role of alpha-tocopherol in preventing disease. <b>2004</b> , 43 Suppl 1, I/18-25	20
1192	["Anti-aging" from a cardiologist's view]. <b>2004</b> , 43, 587-95; quiz 596	
1191	Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C-beta in mesenteric artery and ameliorates wall stiffness in femoral artery of Wistar rats. <b>2004</b> , 47, 1038-46	33
1190	[Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease]. 2004, 29, 4-11	9
1189	Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers. <b>2004</b> , 60, 83-8	24
1188	Postprandial lipid oxidation and cardiovascular disease risk. Current Atherosclerosis Reports, <b>2004</b> , 6, 477&4	54

1187 Oxidative stress and diabetic vascular complications. <b>2004</b> , 4, 247-52	66
1186 What's new in the field of prostate cancer chemoprevention?. <b>2004</b> , 6, 237-42	2
1185 More on vitamin E therapy. <b>2004</b> , 39, 569; author reply 569-70	7
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitod 39, 570-1; author reply 571	chondria?. <b>2004</b> ,
1183 Vitamin E therapy in patients with NASH. <b>2004</b> , 39, 568; author reply 569-70	3
1182 Reply:. <b>2004</b> , 39, 571-572	
1181 The clinical profile of acute hepatitis A infection: is it really so severe?. <b>2004</b> , 39, 57	2; author reply 572-3 1
1180 <b>Reply:. 2004, 39, 569-570</b>	4
1179 Reply:. <b>2004</b> , 39, 572-573	2
1178 LDL oxidative modifications in well- or moderately controlled type 2 diabetes. <b>200</b> 4	<b>4</b> , 20, 298-304 12
1177 Determinants of F2-isoprostane biosynthesis and inhibition in man. <b>2004</b> , 128, 149-	-63 76
1176 Minimal evidence that vitamin supplementation prevents cardiovascular disease. <b>2</b>	<b>004</b> , 8, 24-26
Oxidative stress and antioxidant status in elderly diabetes mellitus and glucose into patients. <b>2004</b> , 39, 269-75	olerance 55
1174 Endothelial Dysfunction, Vascular Damage and Clinical Events. <b>2004</b> , 11, 15-27	1
Selected Presentations from the International Workshop on Endothelial Dysfunction Cardiovascular Disease, Rome, June 48, 2004. <b>2004</b> , 11, 187-204	on and
The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeu <b>2004</b> , 4, 211-7	tic intervention.
The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polym 1171 rationale, recruitment, design, dietary intervention and baseline characteristics of p 2004, 7, 531-42	
1170 Protective role of heme oxygenase in the blood vessel wall during atherogenesis. 2	<b>2004</b> , 82, 351-9 41

1169 Increased levels of superoxide in brains from old female rats. <b>2004</b> , 38, 177-83	12
1168 Effect of vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. <b>2004</b> , 92, 654-8	28
1167 Microvascular complications of diabetes. <b>2004</b> , 33, 215-38, xi-xii	107
1166 Should doctors discourage nutritional supplementation? A cardiovascular perspective. <b>2004</b> , 13, 245-51	1
Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. <b>2004</b> , 43, 629-34	75
1164 Evidence-based guidelines for cardiovascular disease prevention in women. <b>2004</b> , 43, 900-21	80
The renal patient with coronary artery disease: current concepts and dilemmas. <b>2004</b> , 44, 1343-53	35
1162 Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. <b>2004</b> , 173, 1-12	202
Reactive oxygen species in the cerebral circulation: physiological roles and therapeutic implications for hypertension and stroke. <b>2004</b> , 64, 2143-57	33
1160 Antioxidant vitamin supplements and cardiovascular disease. <i>Circulation</i> , <b>2004</b> , 110, 637-41 16.	7 308
1160 Antioxidant vitamin supplements and cardiovascular disease. <i>Circulation</i> , <b>2004</b> , 110, 637-41 16.  1159 Observational versus experimental studies: what's the evidence for a hierarchy?. <b>2004</b> , 1, 341-7	7 308
Observational versus experimental studies: what's the evidence for a hierarchy?. <b>2004</b> , 1, 341-7	118
Observational versus experimental studies: what's the evidence for a hierarchy?. <b>2004</b> , 1, 341-7  Perioperative pharmacotherapy in patients with left ventricular assist devices. <b>2004</b> , 21, 993-1012	118 8
Observational versus experimental studies: what's the evidence for a hierarchy?. <b>2004</b> , 1, 341-7  Perioperative pharmacotherapy in patients with left ventricular assist devices. <b>2004</b> , 21, 993-1012  The role of antioxidant micronutrients in the prevention of diabetic complications. <b>2004</b> , 3, 41-52	118 8 8 <sub>7</sub>
Observational versus experimental studies: what's the evidence for a hierarchy?. 2004, 1, 341-7  Perioperative pharmacotherapy in patients with left ventricular assist devices. 2004, 21, 993-1012  The role of antioxidant micronutrients in the prevention of diabetic complications. 2004, 3, 41-52  Gamma-tocopherolan underestimated vitamin?. 2004, 48, 169-88	118 8 87 198
Observational versus experimental studies: what's the evidence for a hierarchy?. <b>2004</b> , 1, 341-7  Perioperative pharmacotherapy in patients with left ventricular assist devices. <b>2004</b> , 21, 993-1012  The role of antioxidant micronutrients in the prevention of diabetic complications. <b>2004</b> , 3, 41-52  Gamma-tocopherolan underestimated vitamin?. <b>2004</b> , 48, 169-88  Oats, antioxidants and endothelial function in overweight, dyslipidemic adults. <b>2004</b> , 23, 397-403	118 8 87 198

1151	Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. <b>2004</b> , 22, 466-71	21
1150	Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics. <b>2004</b> , 147, 875-82	13
1149	Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. <b>2004</b> , 148, e5	126
1148	Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: the story of GISSI. <b>2004</b> , 148, 193-5	10
1147	The natural treatment of hypertension. <b>2004</b> , 6, 242-8	19
1146	Nutrition and prevention of ischemic stroke: present knowledge, limitations and future perspectives. <b>2004</b> , 14, 97-114	11
1145	Role of apoptosis in atherosclerosis and its therapeutic implications. <b>2004</b> , 107, 343-54	175
1144	Role of oxidative modifications in atherosclerosis. <b>2004</b> , 84, 1381-478	1918
1143	Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. <b>2004</b> , 172, 273-9	68
1142	Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. <b>2004</b> , 172, 361-5	46
1141	Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. <b>2004</b> , 175, 369-76	18
1140	Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. <b>2004</b> , 176, 265-72	39
1139	Vitamin E bioavailability from fortified breakfast cereal is greater than that from encapsulated supplements. <b>2004</b> , 79, 86-92	76
1138	Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation. <b>2004</b> , 79, 54-61	80
1137	Potential synergy of phytochemicals in cancer prevention: mechanism of action. <b>2004</b> , 134, 3479S-3485S	1303
1136	Vitamins, supplements, herbal medicines, and arrhythmias. <b>2004</b> , 12, 73-84	33
1135	Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. <b>2004</b> , 19, 488-93	109
1134	An update on alcohol and atherosclerosis. <b>2004</b> , 15, 673-80	28

Should Doctors Discourage Nutritional Supplementation?A cardiovascular perspective. <b>2004</b> , 13, 245-251	4
1132 Antioxidant supplements for preventing gastrointestinal cancers. <b>2004</b> , CD004183	27
Practical strategies for cardiac disease prevention. Basic steps to ensure better heart health. <b>2004</b> , 115, 41-4	1
Vitamin C has no effect on endothelium-dependent vasomotion and acute endogenous fibrinolysis in healthy smokers. <b>2004</b> , 44, 117-24	34
N-Acetylcysteine in nephrology; contrast nephropathy and beyond. <b>2004</b> , 13, 649-54	28
1128 Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. <b>2004</b> , 38, 48-55	133
Vitamin supplementation: what the gastroenterologist needs to know. <b>2004</b> , 38, 844-54	11
1126 The role of fat-soluble nutrients and antioxidants in preventing heart disease. <b>2004</b> , 56-76	
Vitamin E and other antioxidants in the prevention of cardiovascular disease. <b>2004</b> , 77-98	
1124 What does the lipoprotein oxidation phenomenon mean?. <b>2004</b> , 32, 160-3	
1124 What does the apoprotein oxidation phenomenon mean 2004, 32, 100 3	6
Strategies to reduce oxidative stress in cardiovascular disease. <b>2004</b> , 106, 219-34	152
Strategies to reduce oxidative stress in cardiovascular disease. <b>2004</b> , 106, 219-34	
Strategies to reduce oxidative stress in cardiovascular disease. <b>2004</b> , 106, 219-34  Nutraceuticals. <b>2004</b> ,	152
Strategies to reduce oxidative stress in cardiovascular disease. 2004, 106, 219-34  1122 Nutraceuticals. 2004,  1121 The renal patient with coronary artery diseaseCurrent concepts and dilemmas. 2004, 44, 1343-1353	152 84
Strategies to reduce oxidative stress in cardiovascular disease. 2004, 106, 219-34  Nutraceuticals. 2004,  The renal patient with coronary artery diseaseCurrent concepts and dilemmas. 2004, 44, 1343-1353  Myocarditis from the Chinese sumac tree. 2005, 143, 159-60	152 84 9
Strategies to reduce oxidative stress in cardiovascular disease. 2004, 106, 219-34  Nutraceuticals. 2004,  The renal patient with coronary artery diseaseCurrent concepts and dilemmas. 2004, 44, 1343-1353  Myocarditis from the Chinese sumac tree. 2005, 143, 159-60  Antioxidants and hypertension: another false dawn?. 2005, 23, 1963-6	152 84 9

1115 Stroke: background, epidemiology, etiology and avoiding recurrence. 2005, 1-46

1114	Antioxidant vitamins reduce oxidative stress and ventricular remodeling in patients with acute myocardial infarction. <b>2005</b> , 18, 487-96	25
1113	Vitamin E: absorption, plasma transport and cell uptake. <b>2005</b> , 8, 133-8	69
1112	Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part II. <b>2005</b> , 15, 7-12	4
1111	Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. 2005, 142, 37-46	1760
1110	Effect of ascorbic acid on microcirculation in patients with Type II diabetes: a randomized placebo-controlled cross-over study. <b>2005</b> , 108, 507-13	38
1109	NADPH oxidase and endothelial cell function. <b>2005</b> , 109, 217-26	196
1108	Alpha-tocopherol supplementation favorable effects on blood pressure, blood viscosity and cardiac remodeling of spontaneously hypertensive rats. <b>2005</b> , 16, 251-6	7
1107	Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs. <b>2005</b> , 13, 5787-96	25
1106	Aspirin for the primary prevention of cardiovascular disease: a comprehensive review. <b>2005</b> , 31, 186-93	8
1105	Possible contraindications and adverse reactions associated with the use of ocular nutritional supplements. <b>2005</b> , 25, 179-94	12
1104	Management of dyslipidemia in women in the post-hormone therapy era. <b>2005</b> , 20, 297-305	7
1103	The vitamin E debate: implications for ongoing trials of pre-eclampsia prevention. <b>2005</b> , 112, 684-8	18
1102	Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. <b>2005</b> , 257, 438-45	54
1101	Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. <b>2005</b> , 35, 305-14	68
1100	Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. <b>2005</b> , 59, 196-204	56
1099	Effects of vitamin E on the toxicity of oxidized LDL on endothelial cells in vitro in smokers vs nonsmokers on diets rich in fish. <b>2005</b> , 59, 1282-90	10
1098	Life-style modification in peripheral arterial disease. <b>2005</b> , 29, 2-9	27

1097 Regulation of Weibel-Palade body exocytosis. <b>2005</b> , 15, 302-8	209
12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. <b>2005</b> , 78, 185-93	24
1095 EstrB oxidativo y stidrome de apneas-hipopneas del sue . 2005, 41, 393-399	16
Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City. <b>2005</b> , 5, 4	19
Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. <b>2005</b> , 42, 125-40	30
1092 Chemistry and biology of vitamin E. <b>2005</b> , 49, 7-30	376
1091 Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. <b>2005</b> , 206, 117-28	30
Evidence for a non-antioxidant, dose-dependent role of alpha -lipoic acid in caspase-3 and ERK2 activation in endothelial cells. <b>2005</b> , 10, 657-65	18
1089 [Nutrition]. <b>2005</b> , 94 Suppl 3, III/15-21	0
On the opinion of the European Commission "Scientific Committee on Food" regarding the tolerable upper intake level of vitamin E (2003). <b>2005</b> , 44, 60-2	5
1087 Molecular aspects of atherogenesis: new insights and unsolved questions. <b>2005</b> , 12, 839-53	48
1086 Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. <b>2005</b> , 40, 987-94	95
1085 Antioxidants and atherosclerosis: emerging drug therapies. <i>Current Atherosclerosis Reports</i> , <b>2005</b> , 7, 71-76	14
Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. <b>2005</b> , 5, 91-7	29
1083 What's new in the field of prostate cancer chemoprevention?. <b>2005</b> , 6, 177-82	1
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. <b>2005</b> , 4, 5	568
1081 [Cardiovascular system and aging]. <b>2005</b> , 62, 827-35	2
$_{ m 108o}$ [Antioxidant vitamin supplementation in the prevention of cardiovascular disease]. <b>2005</b> , 62, 615-8	4

Reduction of Soluble E-Selectin after Combined Treatment with Simvastatin and Vitamins C and E. **2005**, 5, 75-80

1078 High-dosage vitamin E supplementation and all-cause mortality. <b>2005</b> , 143, 152-3; author reply 156-8	10
Time-Integrated CRP Level Strongly Predicts PD Patient Outcomes [Nice to Know, but what Should we do about It?. <b>2005</b> , 25, 234-237	1
1076 Widening the horizons of BvidencellNutrition and disease in ecological perspective. <b>2005</b> , 18, 140-148	
1075 High-Dosage Vitamin E Supplementation and All-Cause Mortality. <b>2005</b> , 143, 156	5
1074 High-dosage vitamin E supplementation and all-cause mortality. <b>2005</b> , 143, 150-1; author reply 156-8	14
Scientific evidence to support a vitamin E and heart disease health claim: research needs. <b>2005</b> , 135, 348-53	29
The level of evidence for permitting a qualified health claim: FDA's review of the evidence for selenium and cancer and vitamin E and heart disease. <b>2005</b> , 135, 354-6	25
1071 Nutritional supplementation to prevent cataract formation. <b>2005</b> , 38, 103-119	33
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. <b>2005</b> , 26, 2238-44	236
1069 Dietary Supplements. <b>2005</b> , 248-264	1
Effect of 1-Year Oral ⊞ocopherol Administration on Anticardiolipin Antibodies in Hemodialysis Patients. <b>2005</b> , 27, 193-198	1
Role of antioxidants in atherosclerosis: epidemiological and clinical update. <b>2005</b> , 11, 2017-32	87
1066 Microcirculation of the diabetic foot. <b>2005</b> , 11, 2301-9	74
1065 Nutrition in End-Stage Renal Disease. <b>2005</b> , 214-231	1
Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. <b>2005</b> , 288, H591-600	12
Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: Response to Bhalodkar and Blum. <b>2005</b> , 28, 232-233	
1062 Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?. <b>2005</b> , 289, F227-34	59

# (2005-2005)

1061	Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. <b>2005</b> , 25, 279-86	384
1060	Antioxidant defence during cardiopulmonary bypass surgery. <b>2005</b> , 27, 611-6	42
1059	Contradicted and initially stronger effects in highly cited clinical research. 2005, 294, 218-28	890
1058	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to Genuth, Lachin, and Nathan. <b>2005</b> , 28, 234-235	2
1057	Itraconazole-induced painful neuropathy in a man with type 1 diabetes. 2005, 28, 225	5
1056	Oxidative stress and vascular disease: insights from isoprostane measurement. <b>2005</b> , 51, 14-5	19
1055	Vitamin E supplementation in cardiovascular disease and cancer prevention: Part 1. 2005, 39, 1870-8	46
1054	Vitamin E and the age-related eye disease study supplementation for age-related macular degeneration. <b>2005</b> , 123, 395-6	25
1053	Is there any hope for vitamin E?. <b>2005</b> , 293, 1387-90	56
1052	Inactivation of SRC family tyrosine kinases by reactive oxygen species in vivo. <b>2005</b> , 280, 23918-25	39
1051	Essential nutrients: food or supplements? Where should the emphasis be?. <b>2005</b> , 294, 351-8	82
1050	Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis. 2005, 103, 137-41	65
1049	MedikamentBe Therapie beim Patienten mit stabiler Angina pectoris. 2005, 1, 225-236	
1048	Cost implications of new evidence on prevention of cardiovascular disease. <b>2005</b> , 5, 183-92	1
1047	Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. <b>2005</b> , 3, 717-32	20
1046	The vascular endothelium in diabetes: a practical target for drug treatment?. <b>2005</b> , 9, 101-17	18
1045	Hydrogen peroxide regulation of endothelial exocytosis by inhibition of N-ethylmaleimide sensitive factor. <b>2005</b> , 170, 73-9	35
1044	Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. <b>2005</b> , 6, 2169-80	3

1043	Increased prevalence of diabetes and obesity in patients with salivary gland tumors. <b>2005</b> , 28, 228	13
1042	Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. <b>2005</b> , 174, 7633-44	164
1041	Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects: response to Manning et al. <b>2005</b> , 28, 230; author reply 230-1	2
1040	Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. <b>2005</b> , 51, 125-31	114
1039	Evaluation of the Portable HealthWear Armband: a device to measure total daily energy expenditure in free-living type 2 diabetic individuals. <b>2005</b> , 28, 225-7	68
1038	Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control: Response to Biermann et al <b>2005</b> , 28, 229-230	2
1037	Suboptimal intensity of risk factor modification in PAD. <b>2005</b> , 10, 91-6	23
1036	Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. <b>2005</b> , 263-300	84
1035	Effect of High-Dose Vitamin E on Insulin Resistance and Associated Parameters in Overweight Subjects: Response to Vale. <b>2005</b> , 28, 230-231	1
1034	Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. <b>2005</b> , 28, 233; author reply 234-5	8
1033	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. <b>2005</b> , 3, 1111-24	11
1032	Detection of silent myocardial ischemia in asymptomatic diabetic subjects: response to Wackers et al. <b>2005</b> , 28, 231-2; author reply 232-3	12
1031	Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. <i>Circulation</i> , <b>2005</b> , 112, 1339-46	153
1030	Oxidative-nitrosative stress in hypertension. <b>2005</b> , 3, 231-46	70
1029	Telecare for patients with type 1 diabetes and inadequate glycemic control: response to Montori et al. <b>2005</b> , 28, 228-9; author reply 229-30	6
1028	Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. <b>2005</b> , 294, 56-65	800
1027	Hypoglycemia following a nateglinide overdose in a suicide attempt. <b>2005</b> , 28, 227-8	24
1026	Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. <b>2005</b> , 45, 530-7	118

# (2005-2005)

Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. <b>2005</b> , 101, 1275-1287	145
Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. <b>2005</b> , 31, 197-204	4
Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. <b>2005</b> , 179, 193-200	43
[Functional foods or nutritional-dose supplementations: what does the future hold for micronutrition in ophtalmology?]. <b>2005</b> , 28, 239-42	
1021 Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. <b>2005</b> , 23, 319-30	54
1020 Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. <b>2005</b> , 89, 587-611	42
1019 The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. <b>2005</b> , 240, 143-56	47
1018 Place of drug therapy in the treatment of carotid stenosis. <b>2005</b> , 19, 597-622	4
Effect of 1-Year Oral Tocopherol Administration on Anticardiolipin Antibodies in Hemodialysis Patients. <b>2005</b> , 27, 193-198	4
Effect of glutathione peroxidase mimic ebselen (PZ51) on endothelium and vascular structure of stroke-prone spontaneously hypertensive rats. <b>2005</b> , 14, 366-72	25
1015 Alpha-tocopherol: roles in prevention and therapy of human disease. <b>2005</b> , 59, 380-7	150
Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. <b>2005</b> , 9, 459-76	19
Vitamins E and C pretreatment prevents ovariectomy-induced memory deficits in water maze. <b>2005</b> , 84, 192-9	46
Importance of tocopherols beyond £ocopherol: evidence from animal and human studies. <b>2005</b> , 25, 877-889	86
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. <b>2005</b> , 149, 54-60	252
1010 Effects of Diabetes and Insulin Resistance on Endothelial Functions. <b>2005</b> , 25-46	
1009 Diabetes Mellitus and Heart Disease. <b>2005</b> , 579-628	
1008 [Oxidative stress and sleep apnea-hypopnea syndrome]. <b>2005</b> , 41, 393-9	3

1007	Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. <b>2005</b> , 46, 166-72	314
1006	Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative	104
1005	Endothelial Dysfunction in the Metabolic Syndrome. <b>2005</b> , 321-338	
1004	Dried fruits: excellent in vitro and in vivo antioxidants. <b>2005</b> , 24, 44-50	272
1003	Targets for Pharmacological Modulation of Cardiac Fibrosis. <b>2005</b> , 275-310	1
1002	Interstitial Fibrosis in Heart Failure. <b>2005</b> ,	1
1001	Diabetes and Cardiovascular Disease. 2005,	6
1000	Cardiovascular Biomarkers. <b>2006</b> ,	2
999	Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. <b>2006</b> , 4, 631-47	4
998	Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. <b>2006</b> , 6, 417-32	11
997	Is there a role for real life observational studies in integrating knowledge provided by randomized clinical trials?. <b>2006</b> , 18, 274-6	
996	Systemic markers of inflammationare they useful predictive tools in coronary artery disease?. <b>2006</b> , 40, 262-6	3
995	Antioxidants and Cardiovascular Disease. 2006,	3
994	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. 2006, 399-436	
993	Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. <b>2006</b> , 2, 582-93	290
992	Antioxidants: the good, the bad and the ugly. <b>2006</b> , 22 Suppl B, 61B-65B	16
991	Is vitamin C an effective antihypertensive supplement? A review and analysis of the literature. <b>2006</b> , 5, 60-4	12
990	Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2006</b> , 84, 39-48	26

# (2006-2006)

989	ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,?Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of	184
988	EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and mmittee ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. <b>2006</b> , 48, 824-32	98
987	Peripheral arterial disease: a review of disease awareness and management. <b>2006</b> , 4, 365-79	25
986	Oxidative stress in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. <b>2006</b> , 38, 794-803	124
985	Lack of effect of alpha-tocopherol on in vitro angiogenesis. <b>2006</b> , 72, 12-9	7
984	Nandrolone decanoate impairs exercise-induced cardioprotection: role of antioxidant enzymes. <b>2006</b> , 99, 223-30	47
983	gamma-tocopherol, but not alpha-tocopherol, potently inhibits neointimal formation induced by vascular injury in insulin resistant rats. <b>2006</b> , 41, 544-54	21
982	The Effect of Green Tea Polyphenol on Plasma Glucose, Lipid Levels and Antioxidant Systems in Type 2 Diabetic Patients. <b>2006</b> , 30, 217	1
981	Vitamin E in humans: an explanation of clinical trial failure. <b>2006</b> , 12, 576-82	66
980	Nahrungsergfizung mit Vitalstoffen. Unter besonderer Berfiksichtigung des Diabetikers: Was sinnvoll und notwendig ist. <b>2006</b> , 18, 140-144	
979	Antioxidants. <b>2006</b> , 71-75	
978	Contraindications, adverse reactions and ocular nutritional supplements. <b>2006</b> , 231-241	
977	Long-term efficacy of edaravone in patients with acute myocardial infarction. 2006, 70, 832-7	55
976	Job strain, worksite support, and nutrient intake among employed Japanese men and women. <b>2006</b> , 16, 79-89	20
975	The primary care of Alzheimer disease. <b>2006</b> , 332, 314-33	7
974	Aspirin resistance: mechanisms and clinical implications. <b>2006</b> , 14, 18-25	17
973	Vitamin E in heart transplantation: effects on cardiac gene expression. 2006, 81, 736-45	6
972	Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. <b>2006</b> , 7, 347-50	83

971	Dietary supplements: altered coagulation and effects on bruising. <b>2005</b> , 31, 819-26; discussion 826	38
970	Management of lipid abnormalities associated with end-stage renal disease. <b>2006</b> , 19, 391-401	1
969	Oxidative stress, antioxidants, and vascular damage. <b>2006</b> , 61, 774-7	29
968	Effects of dietary factors on oxidation of low-density lipoprotein particles. <b>2006</b> , 17, 645-58	115
967	Independent design and conduct of clinical trials. <b>2006</b> , 3, 503-7	3
966	The cardiovascular patient's perceptions of complementary and alternative medicine. 2006, 29, 161-4	21
965	The free radical fantasy: a panoply of paradoxes. <b>2006</b> , 1067, 22-6	68
964	Influence of selenomethionine and vitamin E on the antioxidative system in animals with experimentally induced hypercholesterolemia. <b>2006</b> , 111, 137-49	2
963	Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. <b>2006</b> , 11, 65-74	35
962	The management of conditioned nutritional requirements in heart failure. <b>2006</b> , 11, 75-82	47
961	Vitamin E in renal therapeutic regiments. <b>2006</b> , 21, 1790-801	14
960	The role of nitric oxide in early atherosclerosis. <b>2006</b> , 62, 69-78	6
959	Dietary effects on oxidation of low-density lipoprotein and atherogenesis. <i>Current Atherosclerosis Reports</i> , <b>2006</b> , 8, 523-9	20
958	Regulation of antioxidant and oxidant enzymes in vascular cells and implications for vascular disease. <b>2006</b> , 8, 69-78	22
957	Vitamins C and E attenuate apoptosis, beta-adrenergic receptor desensitization, and sarcoplasmic reticular Ca2+ ATPase downregulation after myocardial infarction. <b>2006</b> , 40, 1827-42	46
956	Selective regulation of hydrogen peroxide signaling by receptor tyrosine phosphatase-alpha. <b>2006</b> , 41, 302-10	21
955	Acute administration of vitamin E triggers preconditioning via K(ATP) channels and cyclic-GMP without inhibiting lipid peroxidation. <b>2006</b> , 41, 1092-9	29
954	Mitochondrial DNA deletions and the aging heart. <b>2006</b> , 41, 508-17	57

953	Molecular basis of differences among statins and a comparison with antioxidant vitamins. <b>2006</b> , 98, 34P-41P	44
952	Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. <b>2006</b> , 48, 341-60	62
951	Mechanisms of target organ damage caused by hypertension: therapeutic potential. <b>2006</b> , 111, 81-98	103
950	Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. <b>2006</b> , 112, 501-12	29
949	Oxidized Proteins in Cardiac Ischemia and Reperfusion. <b>2006</b> , 605-649	1
948	Nitric oxide-dependent endothelial function and cardiovascular disease. <b>2006</b> , 61, 326-34	66
947	Treatment of angina: a commentary on new therapeutic approaches. <b>2006</b> , 8, A20-A25	2
946	Antioxidants and diabetes. 2006, 11, 107-125	13
945	Transmitting biological information using oxygen: reactive oxygen species as signalling molecules in cardiovascular pathophysiology. <b>2006</b> , 71, 191-4	11
944	Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications. <b>2006</b> , 6, 77-93	33
943	Diet and Supplements. <b>2006</b> , 351-397	
942	Preventive Cardiology. 2006,	
941	Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. <b>2006</b> , 2, 131-45	41
940	What we learnt from randomized clinical trials and cohort studies of antioxidant vitamin? Focus on vitamin E and cardiovascular disease. <b>2006</b> , 7, 69-72	19
939	Mediterranean diet in the Maghreb: An update. <b>2007</b> , 97, 139-161	6
938	Antioxidant Nutrients and Antioxidant Nutrient-Rich Foods Against Coronary Heart Disease. <b>2006</b> , 195-225	1
937	Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. <i>Circulation</i> , <b>2006</b> , 113, 2566-8 <sup>16.7</sup>	6
936	The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. <b>2006</b> , 13, 341-7	15

935	Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?. 2006, 203, 813-6	58
934	Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. <b>2006</b> , 295, 1681-7	1614
933	Arterial Grafting for Coronary Artery Bypass Surgery. 2006,	3
932	Microvascular changes in the diabetic foot. <b>2006</b> , 5, 149-59	57
931	Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. <b>2006</b> , 26, 1746-52	39
930	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery 16.7 disease). <i>Circulation</i> , <b>2006</b> , 114, 2850-70	286
929	ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of	2378
928	Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee Data Monitoring in Clinical Trials. 2006, to Develop Guidelines for the Management of. <i>Circulation</i> , 2006, 113, e463-654	37
927	Chronic antioxidant supplementation impairs coronary endothelial function and myocardial perfusion in normal pigs. <b>2006</b> , 47, 475-81	36
926	Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. <b>2007</b> , 30, 670-6	83
925	Heart mitochondria: gates of life and death. <b>2008</b> , 77, 334-43	278
924	Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. <b>2007</b> , 75, 261-74	124
923	Aging enhances pressure-induced arterial superoxide formation. <b>2007</b> , 293, H1344-50	64
922	Persistence of contradicted claims in the literature. <b>2007</b> , 298, 2517-26	137
921	Patient selection, statistical presumption, and uncertainty of outcomes. <b>2007</b> , 16, 213-5	
920	The use of vitamin E in type 2 diabetes mellitus. <b>2007</b> , 29, 135-48	39
919	Dietary supplements for the prevention and treatment of coronary artery disease. <b>2007</b> , 13, 83-95	13
918	Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth  Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular	322

917	The roles of alpha-vitamin E and its analogues in prostate cancer. <b>2007</b> , 76, 493-518	8
916	Role of oxidants and antioxidants in atherosclerosis: results of in vitro and in vivo investigations. <b>2007</b> , 12, 265-82	47
915	Angiotensin II-induced reactive oxygen species and the kidney. 2007, 18, 2439-46	200
914	Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. <b>2007</b> , 93, 903-7	340
913	Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. <b>2007</b> , 167, 1593-9	305
912	Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications. 2007, 3, 194-199	3
911	Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis. 2007, 3, 200-208	1
910	Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. <b>2007</b> , 72, 359-63	80
909	Vitamins and minerals: powerful medicine or potent toxins?. <b>2007</b> , 37, 50-60	11
908	Dietary patterns and cardiovascular mortality in the Melbourne Collaborative Cohort Study. <b>2007</b> , 86, 221-9	67
907	Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis. <b>2007</b> , 50, 350-1	4
906	Oxidative Stress and Vascular Disease. 148-164	
905	A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. <b>2007</b> , 167, 1610-8	343
904	NADPH oxidase inhibitors: new antihypertensive agents?. <b>2007</b> , 50, 9-16	125
903	Studies with vitamin E and beta-carotene as single agents do not prove lack of benefit. 2007, 98, 1092-3	1
902	Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. <b>2007</b> , 153, 201-11	174
901	Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. <b>2007</b> , 154, 645.e1-8	28
900	Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. <b>2007</b> , 20, 392-7	153

899	Risk of mortality with vitamin E supplements: the Cache County study. <b>2007</b> , 120, 180-4	43
898	Monitoring micronutrients in cigarette smokers. <b>2007</b> , 377, 14-38	121
897	Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. <b>2007</b> , 77 Suppl 1, S65-70	50
896	Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. <b>2007</b> , 13, 884-92	31
895	Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. 2007, 28, 538-90	55
894	Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. <b>2007</b> , 192, 438-44	58
893	The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. <b>2007</b> , 16, 25-32	51
892	Biomarkers of obesity and subsequent cardiovascular events. <b>2007</b> , 29, 98-114	66
891	Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. <b>2007</b> , 5, 1105-11	14
890	Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in rats. <b>2007</b> , 29, 465-78	7
890 889	Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in rats. 2007, 29, 465-78  Role of oxidative stress in cardiac hypertrophy and remodeling. 2007, 49, 241-8	7 544
	Role of oxidative stress in cardiac hypertrophy and remodeling. <b>2007</b> , 49, 241-8	
889	Role of oxidative stress in cardiac hypertrophy and remodeling. <b>2007</b> , 49, 241-8	544
889	Role of oxidative stress in cardiac hypertrophy and remodeling. <b>2007</b> , 49, 241-8  Effects of flavonoid-containing beverages and EGCG on endothelial function. <b>2007</b> , 26, 366S-372S	544 42
889 888 887	Role of oxidative stress in cardiac hypertrophy and remodeling. 2007, 49, 241-8  Effects of flavonoid-containing beverages and EGCG on endothelial function. 2007, 26, 366S-372S  The alpha-tocopherol transfer protein. 2007, 76, 45-65	544 42 75
889 888 887 886	Role of oxidative stress in cardiac hypertrophy and remodeling. 2007, 49, 241-8  Effects of flavonoid-containing beverages and EGCG on endothelial function. 2007, 26, 366S-372S  The alpha-tocopherol transfer protein. 2007, 76, 45-65  AGE, RAGE, and ROS in diabetic nephropathy. 2007, 27, 130-43	<ul><li>544</li><li>42</li><li>75</li><li>262</li></ul>
889 888 887 886 885	Role of oxidative stress in cardiac hypertrophy and remodeling. 2007, 49, 241-8  Effects of flavonoid-containing beverages and EGCG on endothelial function. 2007, 26, 366S-372S  The alpha-tocopherol transfer protein. 2007, 76, 45-65  AGE, RAGE, and ROS in diabetic nephropathy. 2007, 27, 130-43  The role of protein kinase C activation and the vascular complications of diabetes. 2007, 55, 498-510	<ul><li>544</li><li>42</li><li>75</li><li>262</li><li>330</li></ul>

# (2007-2007)

881	Juice powder concentrate and systemic blood pressure, progression of coronary artery calcium and antioxidant status in hypertensive subjects: a pilot study. <b>2007</b> , 4, 455-62		17
880	Efeito da suplementab de beta-caroteno na pressb arterial de ratos. <b>2007</b> , 20, 39-45		2
879	. 2007,		2
878	Is vitamin E beneficial in chronic liver disease?. <b>2007</b> , 46, 288-90		25
877	Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization. <b>2007</b> , 15, 6262-72		21
876	Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model. <b>2007</b> , 18, 127-33		33
875	Reversal of renal disease: is it enough to inhibit the action of angiotensin II?. 2007, 14, 1343-9		25
874	Vitamin E supplementation and plasma 8-isoprostane and adiponectin in overweight subjects. <b>2007</b> , 15, 386-91		44
873	Clinical pharmacology and therapeutic use of antioxidant vitamins. 2007, 21, 111-27		87
872	Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. <b>2008</b> , 62, 287-99		14
871	The relationship between dose of vitamin E and suppression of oxidative stress in humans. <b>2007</b> , 43, 1388-93		174
870	Nutrition in Pediatric Cardiomyopathy. <b>2007</b> , 24, 59-71		27
869	Oxidative stress and the role of antioxidants in cardiovascular risk reduction. <b>2001</b> , 16, 30-2		1
868	Reactive Oxygen Species, Oxidative Stress, and Vascular Biology in Hypertension. <b>2007</b> , 337-347		9
867	Gender related differential effects of Omega-3E treatment on diabetes-induced left ventricular dysfunction. <b>2007</b> , 304, 255-63		31
866	Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment?. <b>2007</b> , 21, 195-210		64
865	Vitamin intake and risk of coronary disease: observation versus intervention. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 508-14	6	18
864	Antioxidants and CVD in diabetes: where do we stand now. <b>2007</b> , 7, 8-13		23

863	Adverse effects of vitamin E by induction of drug metabolism. <b>2007</b> , 2, 249-56	48
862	The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise. <b>2007</b> , 18, 357-71	114
861	Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis. <b>2008</b> , 10, 1393-7	8
860	Vitamin E transfer from lipid emulsions to plasma lipoproteins: mediation by multiple mechanisms. <b>2008</b> , 43, 663-71	10
859	Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. <b>2008</b> , 9, 17	24
858	Cancer phytotherapeutics: role for flavonoids at the cellular level. 2008, 22, 567-77	117
857	Redox signalling in cardiovascular disease. <b>2008</b> , 2, 823-36	16
856	Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?. <b>2008</b> , 71, 636-43	2
855	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <b>2008</b> , CD007176	173
854	Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. <b>2008</b> , 101, 75D-86D	141
853	Nutritional and anti-inflammatory interventions in chronic heart failure. 2008, 101, 89E-103E	117
852	Selenium inhibits high glucose- and high insulin-induced adhesion molecule expression in vascular endothelial cells. <b>2008</b> , 39, 373-9	30
851	Exercise and immobilization in aging animals: the involvement of oxidative stress and NF-kappaB activation. <b>2008</b> , 44, 202-14	96
850	The evidence for dietary prevention and treatment of cardiovascular disease. 2008, 108, 287-331	230
849	The paradigm of postconditioning to protect the heart. <b>2008</b> , 12, 435-58	99
848	Vitamin E in human health and disease. <b>2008</b> , 45, 417-50	116
847	The effect of strawberries in a cholesterol-lowering dietary portfolio. <b>2008</b> , 57, 1636-44	64
846	Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines2007 Update. <b>2008</b> , 68, 339-58	4

### (2008-2008)

845	Antioxidants preserve redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance. <b>2008</b> , 197, 287-96	65
844	The complex intersection of inflammation and oxidation: implications for atheroprotection. <b>2008</b> , 52, 1379-80	8
843	Diet and Heart Disease. 2008, 181-190	
842	Oxidative Stress in Aging. <b>2008</b> ,	11
841	Atherosclerosis and Oxidant Stress. 2008,	3
840	Risk factors for cardiovascular disease in women: relationship to lipid peroxidation and oxidative stress. <b>2008</b> , 71, 39-44	54
839	How safe is vitamin E supplementation?. <b>2008</b> , 48, 760-74	26
838	Oxidative stress and left ventricular remodelling after myocardial infarction. <b>2009</b> , 81, 457-64	324
837	Vitamin and mineral supplements. <b>2008</b> , 35, 729-47	8
836	Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. <b>2008</b> , 22, 455-67	21
835	Preventing Heart disease: who needs to be concerned and what to do. 2008, 35, 589-607	1
834	Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. <b>2008</b> , 88, 581-609	1055
833	Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. <b>2008</b> , 10, 1631-74	131
832	Antioxidant supplements for preventing gastrointestinal cancers. 2008, CD004183	72
831	Endothelium, ischemia and the good side of oxygen free radicals. <b>2008</b> , 39, 197-203	4
830	Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. <b>2008</b> , 300, 2123-33	615
829	Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. <b>2008</b> , 28, e18-20	23
828	Oxidative stress and platelets. <b>2008</b> , 28, s11-6	198

827	Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. <i>Circulation</i> , <b>2008</b> , 117, 2626-36	16.7	206
826	Nested randomized trials in large cohorts and biobanks: studying the health effects of lifestyle factors. <b>2008</b> , 19, 75-82		29
825	Suppression of the JNK Pathway by Induction of a Metabolic Stress Response Prevents Vascular Injury and Dysfunction. <i>Circulation</i> , <b>2008</b> , 1	16.7	84
824	The antioxidant tempol attenuates pressure overload-induced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet. <b>2008</b> , 295, H2223-30		47
823	Does increased oxidative stress cause hypertension?. <b>2008</b> , 31 Suppl 2, S185-9		112
822	Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. <b>2008</b> , 28, 341-7		224
821	Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. <b>2008</b> , 57, 2794-800		106
820	Kritisch betrachtet: Parenterale Vitamingabe bei asymptomatischen Patienten. <b>2008</b> , 84, 502-506		
819	Opinion on mixed tocopherols, tocotrienol tocopherol and tocotrienols as sources for vitamin E added as a nutritional substance in food supplements - Scientific Opinion of the Panel on Food Additives, Flavourings, Processing aids and Materials in Contact. <b>2008</b> , 6, 640		2
818	Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants. <b>2008</b> , 4, 259-68		30
817	Plasma vitamin C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the European Prospective Investigation into Cancer Norfolk prospective population study. <b>2008</b> , 87, 64-9		85
816	Dietary antioxidants and glucose metabolism. <b>2008</b> , 11, 471-6		27
815	New insights in preventive cardiology and cardiac rehabilitation. 2008, 23, 477-86		6
814	Vitamin E revisited: do new data validate benefits for chronic disease prevention?. 2008, 19, 30-8		61
813	Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. <b>2008</b> , 3, 79-88		22
812	Oxidative stress in vascular senescence: lessons from successfully aging species. <b>2008</b> , 13, 5056-70		68
811	Role of oxidative stress and nitric oxide in atherothrombosis. 2008, 13, 5323-44		127
810	Statin treatment as a confounding factor in human trials with vitamin E. 2008, 138, 1179-81		7

## (2009-2009)

809	<b>2009</b> , 2, 1-8	4
808	Therapeutic interventions and oxidative stress in diabetes. <b>2009</b> , 14, 192-209	21
807	Antiatherogenic effects of vitamin E: the search for the Holy Grail. 2009, 5, 767-74	21
806	Antioxidant supplementation alters cytokine production from monocytes. <b>2009</b> , 29, 741-8	5
805	Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. <b>2009</b> , 15, 3118-25	47
804	Vitamin E does not regress hypercholesterolemic atherosclerosis. <b>2009</b> , 14, 231-41	9
803	Effects of vitamins C and E on the outcome after acute myocardial infarction in diabetics: a retrospective, hypothesis-generating analysis from the MIVIT study. <b>2009</b> , 112, 219-23	20
802	New insights into lipid metabolism in chronic kidney disease: what are the practical implications?. <b>2009</b> , 27, 86-91	7
801	Alpha-tocopherol is ineffective in preventing the decomposition of preformed lipid peroxides and may promote the accumulation of toxic aldehydes: a potential explanation for the failure of antioxidants to affect human atherosclerosis. <b>2009</b> , 11, 1237-48	25
800	Antioxidant treatment for heart failure: friend or foe?. <b>2009</b> , 102, 305-10	20
799	VITAMINS AND MINERALS AS FUNCTIONAL INGREDIENTS. <b>2009</b> , 197-236	
798	The impact of diabetes mellitus on coronary artery disease: new therapeutic approaches. <b>2009</b> , 15, 2037-48	12
797	Do vegetarians have to eat fish for optimal cardiovascular protection?. <b>2009</b> , 89, 1597S-1601S	36
796	Imaging outcomes in cardiovascular clinical trials. <b>2009</b> , 6, 524-31	4
795	Vitamin E does not slow the progression of hypercholesterolemic atherosclerosis. <b>2009</b> , 18, 89-95	7
794	Vitamin E in Disease Prevention 🖪 Critical Appraisal of Vitamin E Supplementation Trials. 2009, 34, 131-140	5
793	Should we manage patients with non-ST segment elevation myocardial infarction with renal failure with an invasive strategy?. <i>Circulation</i> , <b>2009</b> , 120, 828-30	2
	Lipoprotein Oxidation and Modification. <b>2009</b> , 93-110	

791	Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. <b>2009</b> , 296, F830-8	26
790	'Leaky' ryanodine receptors and sudden cardiac death. <b>2009</b> , 84, 343-4	2
789	A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. <b>2009</b> , 169, 659-69	874
788	The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C. <b>2009</b> , 58, 469-78	31
787	Synergy research: vitamins and secondary plant components in the maintenance of the redox-homeostasis and in cell signaling. <b>2009</b> , 16, 2-16	47
786	Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. <i>Clinical Nutrition</i> , <b>2009</b> , 28, 3-9	55
785	Cardioprotection: a radical view Free radicals in pre and postconditioning. 2009, 1787, 781-93	156
7 <sup>8</sup> 4	Elementos relevantes de la dieta en la prevencifi de la enfermedad cardiovascular. 2009, 16, 5-13	
783	Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. <b>2009</b> , 24, 324-42	54
782	Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs. <b>2009</b> , 9, 2468-83	12
781	The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. <b>2009</b> , 16, 112	50
780	Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients. <b>2009</b> , 10, 32	8
779	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. <b>2009</b> , 2, 2	349
778	The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. <b>2009</b> , 20, 781-7	31
777	Vitamin E and prevention of heart disease in high-risk patients. <b>2000</b> , 58, 278-81	6
776	The American Heart Association Dietary Guidelines for 2000: a summary report. <b>2001</b> , 59, 298-306	24
775	Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. <b>2009</b> , 61, 1375-85	92
774	Grapes and cardiovascular disease. <b>2009</b> , 139, 1788S-93S	130

### (2009-2009)

773	Treatment strategies for peripheral artery disease. <b>2009</b> , 10, 1571-86	8
772	Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. <b>2009</b> , 54, 1238-45	59
771	Highly Crosslinked UHMWPE Doped with Vitamin E. <b>2009</b> , 221-236	4
770	Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. <b>2009</b> , 53, 2315-23	88
769	Diabetic cardiomyopathya distinct disease?. <b>2009</b> , 23, 347-60	53
768	Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. <b>2009</b> , 101, 263-9	52
767	Treatment of hypertension in peripheral arterial disease. 2009, CD003075	7
766	Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. <b>2009</b> , 202, 162-8	65
765	Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. <b>2009</b> , 85, 598-606	111
764	Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. <b>2009</b> , 46, 241-81	296
763	AIG1 is a novel Pirh2-interacting protein that activates the NFAT signaling pathway. 2009, E3, 834	0
762	Lipid management in chronic kidney disease, hemodialysis, and transplantation. <b>2009</b> , 38, 223-34	6
761	Changes in vitamin E prescribing for Alzheimer patients. <b>2009</b> , 17, 621-4	10
760	Astaxanthin, oxidative stress, inflammation and cardiovascular disease. <b>2009</b> , 5, 333-42	124
759	Effects of antioxidant supplementation on insulin sensitivity, endothelial adhesion molecules, and oxidative stress in normal-weight and overweight young adults. <b>2009</b> , 58, 254-62	45
758	Modification of HDL structure and function in individuals with diabetes and the haptoglobin 2-2 genotype. <b>2009</b> , 4, 5-8	1
757	The role of diet and nutritional supplements in preventing and treating cardiovascular disease. <b>2009</b> , 24, 433-41	27
756	Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. <b>2009</b> , 27, S32-6	36

755	Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study II Randomized Controlled Trial. <b>2009</b> , 2009, 319-321	1
754	Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study II Randomized Controlled Trial. <b>2009</b> , 2009, 408-410	
753	Vitamins and cardiovascular disease. <b>2009</b> , 101, 1113-31	56
752	Diabetic cardiomyopathy. 2009, 116, 741-60	123
751	The oxidative stress menace to coronary vasculature: any place for antioxidants?. 2009, 15, 3078-90	21
750	Natural products in regression and slowing of progression of atherosclerosis. <b>2010</b> , 11, 794-800	12
749	Diabetes and vascular disease: basic concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities. <b>2010</b> , 8, 526-44	38
748	Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach?. <b>2010</b> , 8, 259-75	44
747	Carbamylated LDL. <b>2010</b> , 51, 25-52	25
746	Role of protein kinase C in diabetic complications. <b>2010</b> , 5, 77-88	3
<ul><li>746</li><li>745</li></ul>	Role of protein kinase C in diabetic complications. <b>2010</b> , 5, 77-88  Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. <b>2010</b> , 15, 674-7	3 29
	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit	
745	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. <b>2010</b> , 15, 674-7	29
745 744	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. <b>2010</b> , 15, 674-7  Nitric oxide and oxidative stress in vascular disease. <b>2010</b> , 459, 923-39	29 494
745 744 743	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. 2010, 15, 674-7  Nitric oxide and oxidative stress in vascular disease. 2010, 459, 923-39  Reconvene and reconnect the antioxidant hypothesis in human health and disease. 2010, 25, 225-43	29 494 26
745 744 743 742	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. 2010, 15, 674-7  Nitric oxide and oxidative stress in vascular disease. 2010, 459, 923-39  Reconvene and reconnect the antioxidant hypothesis in human health and disease. 2010, 25, 225-43  Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia. 2010, 335, 67-74	29 494 26 8
745 744 743 742 741	Prevention of steroid-induced osteonecrosis by intravenous administration of vitamin E in a rabbit model. 2010, 15, 674-7  Nitric oxide and oxidative stress in vascular disease. 2010, 459, 923-39  Reconvene and reconnect the antioxidant hypothesis in human health and disease. 2010, 25, 225-43  Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia. 2010, 335, 67-74  Secondary prevention strategies for coronary heart disease. 2010, 29, 8-24  Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. 2010,	29 494 26 8

# (2010-2010)

737	Role of oxidative stress in high-glucose- and diabetes-induced increased expression of Gq/11 <sup>1</sup> proteins and associated signaling in vascular smooth muscle cells. <b>2010</b> , 49, 1395-405	14
736	The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. <b>2010</b> , 22, 77-90	41
735	. 2010,	9
734	Reexamination of a meta-analysis of the effect of antioxidant supplementation on mortality and health in randomized trials. <b>2010</b> , 2, 929-49	50
733	Influence of Vascular Oxidative Stress and Inflammation on the Development and Progression of Atherosclerosis. <b>2010</b> , 4, 521-534	7
732	Micronutrient concentrations and subclinical atherosclerosis in adults with HIV. <b>2010</b> , 92, 266-7; author reply 267	1
731	Nutrition, supplements, and vitamins in platelet function and bleeding. <i>Circulation</i> , <b>2010</b> , 121, 1033-44 16.7	59
730	Vitamin E and cardiovascular disease. <b>2010</b> , 17, e56-65	96
729	Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. <b>2010</b> , 24, 1-8	131
728	Rapid cellular enrichment of eicosapentaenoate after a single intravenous injection of a novel medium-chain triacylglycerol:fish-oil emulsion in humans. <b>2010</b> , 91, 875-82	26
727	Anticancer vitamins du JourThe ABCED's so far. <b>2010</b> , 172, 1-3	36
726	Cardiovascular Disease in Patients with Chronic Kidney Disease. <b>2010</b> , 128-144	1
725	Oxidative Stress and Heart Failure. <b>2010</b> , 221-242	
724	Reactive oxygen/nitrogen species and the myocardial cell homeostasis: an ambiguous relationship. <b>2010</b> , 13, 1899-910	13
723	Vitamin E and risk of cardiovascular diseases: a review of epidemiologic and clinical trial studies. <b>2010</b> , 50, 420-40	49
722	Biomarkers of oxidative stress in overweight men are not influenced by a combination of antioxidants. <b>2010</b> , 44, 522-8	4
721	Oxidative stress-mediated cardiac mast cell degranulation. <b>2010</b> , 92, 1293-1301	7
720	Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. <b>2010</b> , 12, 209-17	25

719	Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. <b>2010</b> , 341, c5702	233
718	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. <b>2010</b> , 11, 675-84	98
717	Effect of N-acetylcysteine on sympathetic hyperinnervation in post-infarcted rat hearts. 2010, 85, 137-46	35
716	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. <b>2010</b> , 298, F763-70	88
715	Multivitamin use and the risk of myocardial infarction: a population-based cohort of Swedish women. <b>2010</b> , 92, 1251-6	37
714	Haptoglobin: basic and clinical aspects. <b>2010</b> , 12, 293-304	196
713	Prevention of Type 2 and Gestational Diabetes. 49-110	
712	The renal effects of blood glucose-lowering plant-derived extracts in diabetes mellitusan overview. <b>2010</b> , 32, 132-8	12
711	Safety considerations and potential interactions of vitamins: should vitamins be considered drugs?. <b>2010</b> , 44, 311-24	44
710	Antioxidants: benefits and risks for long-term health. <b>2010</b> , 67, 103-7	52
709	A review of select vitamins and minerals used by postmenopausal women. <b>2010</b> , 66, 370-80	28
709 708	A review of select vitamins and minerals used by postmenopausal women. <b>2010</b> , 66, 370-80  Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. <b>2010</b> , 63, 1053-8	28
	Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical	
708	Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. <b>2010</b> , 63, 1053-8  Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular	33
7º8 7º7	Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. 2010, 63, 1053-8  Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. 2010, 87, 313-21  Nutritional epidemiology in the context of nitric oxide biology: a risk-benefit evaluation for dietary	<ul><li>33</li><li>53</li></ul>
708 707 706	Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. 2010, 63, 1053-8  Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. 2010, 87, 313-21  Nutritional epidemiology in the context of nitric oxide biology: a risk-benefit evaluation for dietary nitrite and nitrate. 2010, 22, 110-9  Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and	<ul><li>33</li><li>53</li><li>81</li></ul>
708 707 706 705	Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. 2010, 63, 1053-8  Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. 2010, 87, 313-21  Nutritional epidemiology in the context of nitric oxide biology: a risk-benefit evaluation for dietary nitrite and nitrate. 2010, 22, 110-9  Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. 2010, 12, 537-77	<ul><li>33</li><li>53</li><li>81</li></ul>

# (2011-2010)

701	Oxidants and Endothelial Dysfunction. <b>2010</b> , 243-274	4
700	What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?. <b>2010</b> , 28, 106-23	9
699	Natural antioxidants and hypertension: promise and challenges. <b>2010</b> , 28, e20-32	106
698	Nutraceuticals and atherosclerosis: human trials. <b>2010</b> , 28, 202-15	151
697	Redox sensing: orthogonal control in cell cycle and apoptosis signalling. <b>2010</b> , 268, 432-48	128
696	Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. <b>2010</b> , 211, 69-76	49
695	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. <b>2010</b> , 211, 25-7	43
694	Evidence-based nutrition: Does it differ from evidence-based medicine?. <b>2010</b> , 42, 475-86	21
693	Antiatherosclerotic Effects of Dietary Flavonoids: Insight into their Molecular Action Mechanism at the Target Site. <b>2010</b> , 299-318	1
692	Impact of platinum-based chemotherapy on the progression of atherosclerosis. <b>2011</b> , 14, 31-40	27
691	Mythology of Antioxidant Vitamins?. <b>2011</b> , 16, 149-159	
	Mychology of Atteloxidatic Vicanimis 2011, 10, 115 155	1
690	Aging and the effects of vitamins and supplements. <b>2011</b> , 27, 591-607	3
690 689		
	Aging and the effects of vitamins and supplements. <b>2011</b> , 27, 591-607  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and	3
689	Aging and the effects of vitamins and supplements. <b>2011</b> , 27, 591-607  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. <b>2011</b> , 21, 211-8	26
689	Aging and the effects of vitamins and supplements. <b>2011</b> , 27, 591-607  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. <b>2011</b> , 21, 211-8  Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. <b>2011</b> , 58, 83-6  Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical	3 26 69
689 688 687	Aging and the effects of vitamins and supplements. 2011, 27, 591-607  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. 2011, 21, 211-8  Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. 2011, 58, 83-6  Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. 2011, 8, 445-456  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus	<ul><li>3</li><li>26</li><li>69</li><li>6</li></ul>

683	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. <b>2011</b> ,	6
682	Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-year follow-up from a randomized, controlled study. <b>2011</b> , 30, 1200-1	13
681	Nutrition and human health from a sex-gender perspective. <b>2011</b> , 32, 1-70	88
680	Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. <b>2011</b> , 219, 240-4	27
679	Synergistic/Additive Health Effects of Fish Oil and Bio-Active Compounds. <b>2011</b> , 177-203	
678	Measures of neurological impairment and disability in multiple sclerosis. 56-64	
677	The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. 244-252	2
676	. 2011,	220
675	References. <b>2011</b> , 193-223	
674	Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients. <b>2011</b> , 5, 229-40	1
673	The antioxidant paradox in diabetes mellitus. <b>2011</b> , 18, 266-78	46
672	Pathophysiology of atherosclerosis: the role of inflammation. <b>2011</b> , 17, 4089-110	86
671	Vitamin E in oxidant stress-related cardiovascular pathologies: focus on experimental studies. <b>2011</b> , 17, 2155-69	4
670	Astaxanthin: a potential therapeutic agent in cardiovascular disease. <b>2011</b> , 9, 447-65	224
669	Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. <b>2011</b> , 342, 135-42	137
668	Preface: Reflections on a Career in Health Research, International Collaboration and Mentoring. <b>2011</b> , 33, 363-372	O
667	Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. <b>2011</b> , 65, 63-9	44
666	Cellular and molecular mechanisms of vascular injury in diabetespart II: cellular mechanisms and therapeutic targets. <b>2011</b> , 54, 75-9	41

665	Countermeasures for space radiation induced adverse biologic effects. <b>2011</b> , 48, 1460-1479	13
664	Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway. <b>2011</b> , 50, 700-9	18
663	Reactive oxygen species in cardiovascular disease. <b>2011</b> , 51, 978-92	526
662	Vitamins C and E: beneficial effects from a mechanistic perspective. <b>2011</b> , 51, 1000-13	515
661	Clinical trials of antioxidants as cancer prevention agents: past, present, and future. 2011, 51, 1068-84	167
660	Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. <b>2011</b> , 1813, 1323-32	116
659	Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. <b>2011</b> , 255-288	16
658	CaMKII in the cardiovascular system: sensing redox states. <b>2011</b> , 91, 889-915	162
657	Vitamin E, diabetes and related diseases: an update. <b>2011</b> , 4, 3-9	4
656	Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. <b>2011</b> , 26, 546-50	309
655	Effect of fruit and vegetable concentrates on endothelial function in metabolic syndrome: a randomized controlled trial. <b>2011</b> , 10, 72	15
654	Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. <b>2011</b> , 10, 58	23
653	Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: A randomized controlled study. <b>2011</b> , 8, 42	46
652	毌ocotrienol quinone modulates oxidative stress response and the biochemistry of aging. <b>2011</b> , 21, 3693-8	73
651	Tocopherol and carotenoid content of foods commonly consumed in Costa Rica. <b>2011</b> , 24, 202-216	23
650	Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. <b>2011</b> , 26, 832-8	9
649	Diabetic cardiomyopathy and oxidative stress: role of antioxidants. <b>2011</b> , 9, 225-30	19
648	Tocotrienols and cardiovascular health. <b>2011</b> , 17, 2147-54	31

647	Oxidative stress and mitochondrial dysfunction in type 2 diabetes. <b>2011</b> , 17, 3947-58	85
646	Oxidative stress and endothelial dysfunction: therapeutic implications. <b>2011</b> , 43, 259-72	82
645	Prevention of intracerebral hemorrhage recurrence. <b>2011</b> , 17, 1304-17	3
644	Association between plasma vitamin C concentrations and blood pressure in the European prospective investigation into cancer-Norfolk population-based study. <b>2011</b> , 58, 372-9	25
643	Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <b>2011</b> , 306, 1549-56	1150
642	Antioxidants in the treatment of diabetes. <b>2011</b> , 7, 106-25	126
641	Seasonal effects on bioactive compounds and antioxidant capacity of six economically important brassica vegetables. <i>Molecules</i> , <b>2011</b> , 16, 6816-32	60
640	Traditional Chinese Medicine. <b>2011</b> ,	1
639	Polymorphisms in the CD36/FAT gene are associated with plasma vitamin E concentrations in humans. <b>2011</b> , 93, 644-51	36
638	DSM Science & Technology Awards (south) event 2011: the role of micronutrients in human nutrition. <b>2011</b> , 58, 297-300	
637	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <b>2011</b> , 2, 265-78	19
636	The Role of Antioxidant Vitamins in Cardiovascular Disease. <b>2011</b> , 27, 19-26	
635	Studies on Renal Disorders. <b>2011</b> ,	3
634	Targeting vascular redox biology through antioxidant gene delivery: a historical view and current perspectives. <b>2011</b> , 6, 89-102	5
633	Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. <b>2011</b> , 17, 1610-8	178
632	Perspective: Why There Must Be a Meditative Medicine. <b>2011</b> , 17, 274-278	
631	Atlas of Atherosclerosis and Metabolic Syndrome. 2011,	5
630	N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study. <b>2011</b> , 31, 545-50	17

629	Alternative therapies useful in the management of diabetes: A systematic review. <b>2011</b> , 3, 504-12		134
628	Nutraceuticals and Cancer. 2012,		5
627	Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney. <b>2012</b> , 303, F576-83		16
626	The perilous state of independent randomized clinical trials and related applied research in Canada. <b>2012</b> , 184, 1997-2002		6
625	Protective Nutrients. <b>2012</b> , 47, 110-122		
624	Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies?. <b>2012</b> , 18, 4358-69		26
623	Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. <b>2012</b> , 35, 1102-10		126
622	Selective divalent copper chelation for the treatment of diabetes mellitus. <b>2012</b> , 19, 2828-60		55
621	Assessing causal relationships between treatments and clinical outcomes: always read the fine print. <b>2012</b> , 47, 626-32		3
620	Vitamins - wrong approaches. <b>2012</b> , 82, 327-32		6
620	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the	16.7	268
	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College	16.7	
619	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Vitamin e and omega-3: what to believe: observational studies or randomized controlled trials?.nd	16.7	268
619	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Vitamin e and omega-3: what to believe: observational studies or randomized controlled trials?.nd 2012, 13, 166-8 racic Surgeons. <i>Circulation</i> , 2012, 126, 3097-137	16.7	268
619 618 617	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Vitamin e and omega-3: what to believe: observational studies organdomized controlled trials? Ind 2012, 13, 66-8 racic Surgeons. <i>Circulation</i> , 2012, 126, 3097-137  The malnutrition of obesity: micronutrient deficiencies that promote diabetes. 2012, 2012, 103472  Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. 2012,	16.7	268 2 145
619 618 617 616	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Vitamin e and omega-3: what to believe: observational studies or randomized controlled trials?.nd 2012, 13, 66-8 racic Surgeons. <i>Circulation</i> , 2012, 126, 3097-137  The malnutrition of obesity: micronutrient deficiencies that promote diabetes. 2012, 2012, 103472  Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. 2012, 2012, 569654  Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms.	16.7	268 2 145 91
619 618 617 616 615	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Vitamin e and omega-3: what to believe: observational studies or randomized controlled trials?.nd 2012, 13, 66-8 racic Surgeons. <i>Circulation</i> , 2012, 126, 3097-137  The malnutrition of obesity: micronutrient deficiencies that promote diabetes. 2012, 2012, 103472  Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. 2012, 2012, 569654  Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. 2012, 20, 77-83  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology		268 2 145 91 80

611	Astaxanthin in cardiovascular health and disease. <i>Molecules</i> , <b>2012</b> , 17, 2030-48	4.8	104
610	Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses		45
609	Relation of serum Hand Ecocopherol levels to cardiovascular disease-related mortality among Japanese men and women. <b>2012</b> , 22, 402-10		26
608	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the		139
607	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American		1138
606	College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?. <b>2012</b> , 30, 227-33		33
605	Differences in pulse pressure day variability between the brachial artery and the aorta in healthy subjects. <b>2012</b> , 6, 34		7
604	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. <b>2012</b> , 223, 86-94		88
603	Let's (not) do it again: secondary prevention of cardiovascular disease in women. <b>2012</b> , 21, 108-9		
602	Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. <b>2012</b> , 41, 828-43		107
601	Antioxidant therapy in hemodialysis patients: a systematic review. <b>2012</b> , 81, 233-46		73
600	Do dietary supplements have beneficial health effects in industrialized nations: what is the evidence?. <b>2012</b> , 36, 159-68		33
599	Micronutriments et risque cardiovasculaire. <b>2012</b> , 26, 14-21		1
598	Synthetic Antioxidants. <b>2012</b> , 381-388		1
597	The role of micronutrients in heart failure. <b>2012</b> , 112, 870-86		57
596	Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations. <b>2012</b> , 65, 16-29		12
595	Actions of "antioxidants" in the protection against atherosclerosis. <b>2012</b> , 53, 863-84		93
594	Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. 2012, 110, 1661-77		183

593	Health Benefits of Phytochemicals in Whole Foods. <b>2012</b> , 293-310	6
592	Oxidation of low-density lipoprotein by iron at lysosomal pH: implications for atherosclerosis. <b>2012</b> , 51, 3767-75	26
591	Encyclopedia of Sustainability Science and Technology. <b>2012</b> , 3443-3449	
590	Antioxidants for chronic kidney disease. <b>2012</b> , 10, CD008176	66
589	Resveratrol in cholesterol metabolism and atherosclerosis. <b>2012</b> , 15, 763-73	43
588	Total antioxidant capacity from diet and risk of myocardial infarction: a prospective cohort of women. <b>2012</b> , 125, 974-80	61
587	Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. <b>2012</b> , 23, 628-32	46
586	Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. <b>2012</b> , 32, 727-40	87
585	Haptoglobin genotype and its role in determining heme-iron mediated vascular disease. <b>2012</b> , 66, 1-6	45
584	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <b>2012</b> , CD007176	301
583	Atherosclerotic Cardiovascular Disease. <b>2012</b> , 745-805	1
582	Microvascular Changes in the Diabetic Foot. <b>2012</b> , 185-201	2
581	Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. <i>Current Atherosclerosis Reports</i> , <b>2012</b> , 14, 476-83	93
580	Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure. <b>2012</b> , 8, 101-11	17
579	Antioxidant-induced stress. 2012, 13, 2091-109	88
578	Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <b>2012</b> , 47, S1-30, S31-54	36
577	Coronary Artery Disease. <b>2012</b> ,	2
576	Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase?. <b>2012</b> , 3, 30	120

575	Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system. <b>2012</b> , 3, 93	29
574	Dietary Supplements and Cardiovascular Disease: What is the Evidence and What Should We Recommend?. <b>2012</b> ,	
573	Role of Oxidized Lipids in Atherosclerosis. 2012,	
57 <sup>2</sup>	The Use of Functional Foods in the Metabolic Syndrome. <b>2012</b> , 8, 25-44	
571	Ten tips for safer prescribing by non-medical prescribers. <b>2012</b> , 10, 251-256	2
570	Vascular Smooth Muscle Cells and the Comparative Pathology of Atherosclerosis. <b>2012</b> ,	
569	Lipid Peroxidation and Antioxidants in Arterial Hypertension. 2012,	5
568	Targeting NADPH oxidases in vascular pharmacology. <b>2012</b> , 56, 216-31	162
567	Effects of aging on angiogenesis. <b>2012</b> , 110, 1252-64	157
566	Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. <b>2012</b> , 111, 245-59	483
565	Antioxidant vitamins and mineral supplementation, life span expansion and cancer incidence: a critical commentary. <b>2012</b> , 51, 769-81	51
564	Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. <b>2012</b> , 36, 190-8	84
563	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. <b>2012</b> , 17, 325-44	240
562	Resveratrol in cardiovascular disease: what is known from current research?. <b>2012</b> , 17, 437-48	70
561	Chronic hydrogen-rich saline treatment reduces oxidative stress and attenuates left ventricular hypertrophy in spontaneous hypertensive rats. <b>2012</b> , 365, 233-42	27
560	Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?. <b>2012</b> , 12, 274-9	11
559	Haptoglobin genotype and its role in diabetic cardiovascular disease. <b>2012</b> , 5, 423-35	37
558	Vitamin status in elderly people in relation to the use of nutritional supplements. <b>2012</b> , 16, 206-12	27

557	Chemoprevention of prostate cancer: an updated view. <b>2012</b> , 30, 189-94	17
556	Microvascular reactivity in response to smoking and oral antioxidants in humans. <b>2012</b> , 19, 86-93	7
555	Estrogen-dependent inhibition of dextrose-induced endoplasmic reticulum stress and superoxide generation in endothelial cells. <b>2012</b> , 52, 2161-7	31
554	Physiological regulation of cardiac contractility by endogenous reactive oxygen species. 2012, n/a-n/a	17
553	Physiological regulation of cardiac contractility by endogenous reactive oxygen species. <b>2012</b> , 205, 26-40	5
552	N-acetylcysteine may improve residual renal function in hemodialysis patients: a pilot study. <b>2012</b> , 16, 512-6	13
551	Pharmacologic strategies to target oxidative stress in heart failure. <i>Current Heart Failure Reports</i> , 2.8 2.9, 14-22	23
550	Diabetes-associated macrovascular complications: cell-based therapy a new tool?. <b>2013</b> , 44, 557-75	13
549	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. 2013, 56, 1884-7	1
548	Molecular aspects of the cardioprotective effect of exercise in the elderly. <b>2013</b> , 25, 487-97	23
547	Medical strategies to reduce amputation in patients with type 2 diabetes. <b>2013</b> , 30, 893-900	26
546	Biological markers of oxidative stress: Applications to cardiovascular research and practice. <b>2013</b> , 1, 483-91	476
545	Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection. <b>2013</b> , 54, 2307-14	49
544	Cardiac metabolism in heart failure: implications beyond ATP production. <b>2013</b> , 113, 709-24	550
543	Dietary bioactive compounds and their health implications. <b>2013</b> , 78 Suppl 1, A18-25	305
542	Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. <b>2013</b> , 173, 1682-92	81
541	NADPH oxidases in heart failure: poachers or gamekeepers?. <b>2013</b> , 18, 1024-41	140
540	Diabetic Retinopathy. <b>2013</b> , 925-939	10

539	Evidence for antioxidants consumption in the coronary blood of patients with an acute myocardial infarction. <b>2013</b> , 35, 41-7	6
538	Secondary reactive oxygen species production after PDT during pulmonary tumor growth in sera of nude mice. <b>2013</b> , 10, 62-71	7
537	Position of the academy of nutrition and dietetics: functional foods. <b>2013</b> , 113, 1096-103	88
536	Patient selection and vitamin E treatment in diabetes mellitus. <b>2013</b> , 11, 319-26	15
535	The role of redox signaling in epigenetics and cardiovascular disease. <b>2013</b> , 18, 1920-36	85
534	Alterations in mitochondrial function in cardiac hypertrophy and heart failure. 2013, 18, 645-56	48
533	Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions. <b>2013</b> , 5, 465-78	10
532	Oxidative stress and pathological changes after coronary artery interventions. <b>2013</b> , 61, 1471-81	76
531	Oxidative inhibition of the vascular Na+-K+ pump via NADPH oxidase-dependent II-subunit glutathionylation: implications for angiotensin II-induced vascular dysfunction. <b>2013</b> , 65, 563-572	25
530	Redox signaling in cardiovascular health and disease. <b>2013</b> , 61, 473-501	144
530 529	Redox signaling in cardiovascular health and disease. <b>2013</b> , 61, 473-501  Myocardial energetics in heart failure. <b>2013</b> , 108, 358	144
529	Myocardial energetics in heart failure. <b>2013</b> , 108, 358	106
529 528	Myocardial energetics in heart failure. <b>2013</b> , 108, 358  Micronutrient supplements: Who needs them? A personal view. <b>2013</b> , 38, 191-200  Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even	106
529 528 527	Myocardial energetics in heart failure. 2013, 108, 358  Micronutrient supplements: Who needs them? A personal view. 2013, 38, 191-200  Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. 2013, 145, 162-7	106 4 29
529 528 527 526	Myocardial energetics in heart failure. 2013, 108, 358  Micronutrient supplements: Who needs them? A personal view. 2013, 38, 191-200  Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. 2013, 145, 162-7  Treatment of hypertension in peripheral arterial disease. 2013, CD003075  Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic	106 4 29 20
529 528 527 526 525	Myocardial energetics in heart failure. 2013, 108, 358  Micronutrient supplements: Who needs them? A personal view. 2013, 38, 191-200  Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. 2013, 145, 162-7  Treatment of hypertension in peripheral arterial disease. 2013, CD003075  Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. 2013, 346, f10  The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. 2013,	106 4 29 20 305

# (2013-2013)

521	Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. <b>2013</b> , 2013, 248563		88
520	Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. <b>2013</b> , 304, R917-28		46
519	Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications. <b>2013</b> , 124, 1-15		74
518	Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. <b>2013</b> , 2, e000364		27
517	Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. <b>2013</b> , 2, e000086		40
516	Knock, knock: who's there?: Nox1. Circulation, 2013, 127, 1850-2	16.7	1
515	Stable Ischemic Heart Disease/Chronic Stable Angina. <b>2013</b> , 131-152		
514	Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. <b>2013</b> , 6, 20-5		15
513	Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. <b>2013</b> , 288, 18077-92		162
512	Anti-stiffness effect of apocynin in deoxycorticosterone acetate-salt hypertensive rats via inhibition of oxidative stress. <b>2013</b> , 36, 306-12		18
511	Health-promoting components of fruits and vegetables in the diet. <b>2013</b> , 4, 384S-92S		625
510	Is there a Role for Antioxidants in the Treatment of Stable Angina?. <b>2013</b> , 19, 1601-1615		1
509	The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?. <b>2013</b> , 43, 443-52		2
508	Endothelium Aging and Vascular Diseases. 2013,		2
507	Free radicals and antioxidants: Myths, facts and mysteries. <b>2013</b> , 7, 91-113		6
506	Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population. <b>2013</b> , 8, e60479		16
505	The association between vitamin D and vascular stiffness in adolescents with and without type 1 diabetes. <b>2013</b> , 8, e77272		20
504	Analysis, Presentation, and Interpretation of Dietary Data. <b>2013</b> , 125-140		

503 Disease and Therapy: A Role for Oxidants. **2013**,

502	What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations. <b>2013</b> , 8, 1505-17	30
501	Oxidative Stress and Antioxidant Therapy in Chronic Kidney and Cardiovascular Disease. 2013,	2
500	Ten tips for safer prescribing by non-medical prescribers. <b>2013</b> , 8, 24-29	
499	In vitro preventive effects of nitrate tolerance by a polyphenol-enriched extract of Hibiscus sabdariffa. <b>2013</b> , 5, 40-46	
498	The need for randomization in animal trials: an overview of systematic reviews. <b>2014</b> , 9, e98856	147
497	The antioxidant advantage of the Mediterranean diet in cardiovascular disease. <b>2014</b> , 35	4
496	Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. <b>2014</b> , 124, 5159-74	30
495	Limiting reductive stress for treating in-stent stenosis: the heart of the matter?. <b>2014</b> , 124, 5092-4	8
494	Anticancer Effects of Grape Seed Extract on Human Cancers: A Review. <b>2014</b> , s8,	8
493	Vitamin E. <b>2014</b> ,	1
492	Vitamin E and Vascular Protection in Diabetes. <b>2014</b> , 157-163	
491	Vitamin E supplementation for adults with diabetes mellitus. <b>2014</b> ,	
490	Reactive Oxygen Species (ROS) Signaling in Cardiac Remodeling and Failure. <b>2014</b> , 951-992	3
489	Review: evidence for the effect of vitamin D supplementation on many patient outcomes was assessed. <b>2014</b> , 161, JC4	
488	Vitamins in dialysis: who, when and how much?. <b>2014</b> , 36, 638-50	13
487	Limitations of observational evidence: implications for evidence-based dietary recommendations. <b>2014</b> , 5, 7-15	83
486	Natural products for the management of type 2 diabetes mellitus and comorbid conditions. <b>2014</b> , 54, e304-18; quiz e319-21	18

485	Hypertension, Menopause and Natural Antioxidants in Foods and the Diet. <b>2014</b> , 225-231	1
484	The role of vitamin supplementation in the prevention of cardiovascular disease events. <b>2014</b> , 37, 576-81	18
483	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. <b>2014</b> , 9, 641-658	1
482	Targeting cardiac hypertrophy: toward a causal heart failure therapy. <b>2014</b> , 64, 293-305	55
481	Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?. <b>2014</b> , 19, 107-17	60
480	Antioxidant Use in Humans <b>L</b> uccesses and Failures. <b>2014</b> , 3967-3985	
479	Antioxidant Supplementation and Therapies. <b>2014</b> , 183-209	1
478	Mitochondria and Oxidative Stress in Diabetes. <b>2014</b> , 63-92	
477	Modulation of arachidonic Acid metabolism in the rat kidney by sulforaphane: implications for regulation of blood pressure. <b>2014</b> , 2014, 683508	11
476	CaMKII oxidative activation and the pathogenesis of cardiac disease. <b>2014</b> , 73, 112-6	92
476 475	CaMKII oxidative activation and the pathogenesis of cardiac disease. <b>2014</b> , 73, 112-6  Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. <b>2014</b> , 46, 255-60	92
	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible	
475	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. <b>2014</b> , 46, 255-60	2
475 474	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. <b>2014</b> , 46, 255-60  Studies in Diabetes. <b>2014</b> ,  Identifying and interpreting novel targets that address more than one diabetic complication: a	2
475 474 473	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. <b>2014</b> , 46, 255-60  Studies in Diabetes. <b>2014</b> ,  Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. <b>2014</b> , 5, 1-20	2 1 3
475 474 473 472	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. 2014, 46, 255-60  Studies in Diabetes. 2014,  Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. 2014, 5, 1-20  Oxidative Stress and Cardiovascular Disease in Diabetes. 2014, 189-235	2 1 3
475 474 473 472 471	Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis. 2014, 46, 255-60  Studies in Diabetes. 2014,  Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. 2014, 5, 1-20  Oxidative Stress and Cardiovascular Disease in Diabetes. 2014, 189-235  Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus. 2014, 187-201  Joint British Societies' consensus recommendations for the prevention of cardiovascular disease	2 1 3 2

467	Stress response signaling pathways may lead to mitochondrial biogenesis. <b>2014</b> , 63, 1831-2	6
466	Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. 2014, 2, 495-503	60
465	Vascular Aging and Free Radicals. <b>2014</b> , 1365-1382	
464	Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. <b>2014</b> , 142, 375-415	354
463	Vitamin E-gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review. <b>2014</b> , 14, 81-101	87
462	Redox signaling in cardiac renewal. <b>2014</b> , 21, 1660-73	17
461	Oxidative stress during extracorporeal circulation. <b>2014</b> , 46, 937-43	47
460	Absence of an effect of vitamin E on protein and lipid radical formation during lipoperoxidation of LDL by lipoxygenase. <b>2014</b> , 76, 61-8	12
459	Pharmacological approaches to coronary microvascular dysfunction. <b>2014</b> , 144, 283-302	20
458	Polypharmacy in heart failure: drugs to use and avoid. <b>2014</b> , 10, 577-90	8
457	Chitosan/tripolyphosphate-nanoliposomes core-shell nanocomplexes as vitamin E carriers: shelf-life and thermal properties. <b>2014</b> , 49, 1367-1374	12
456	Regarding manuscript: "resuscitation outcomes consortium-amiodarone, lidocaine, or placebo study: rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trial". <b>2014</b> , 168, e19-20	1
455	Salvianolic acid B protects human endothelial progenitor cells against oxidative stress-mediated dysfunction by modulating Akt/mTOR/4EBP1, p38 MAPK/ATF2, and ERK1/2 signaling pathways. <b>2014</b> , 90, 34-49	55
454	Dynamic changes in myocardial matrix and relevance to disease: translational perspectives. <b>2014</b> , 114, 916-27	88
453	Sowing the seeds of health: is the era of food prescriptions coming?. <b>2014</b> , 77, 273-4	
452	Myocardial ischemic reperfusion induces de novo Nrf2 protein translation. <b>2014</b> , 1842, 1638-47	52
45 <sup>1</sup>	Dietary interactions with the bacterial sensing machinery in the intestine: the plant polyphenol case. <b>2014</b> , 5, 64	12
450	Review: vitamin D3 supplementation may reduce mortality in adults; vitamin D2 does not. <b>2014</b> , 161, JC5	1

449 Dietary Factors in Geriatric Neurology. **2014**, 645-668

448	Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease. <b>2015</b> , 38, 570-6	66
447	Hypertension as a Risk Factor for Atherosclerosis. <b>2015</b> , 63-75	
446	Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes. <b>2015</b> , 14, 19-28	1
445	Antioxidants in Cardiovascular Therapy: Panacea or False Hope?. Frontiers in Cardiovascular Medicine, <b>2015</b> , 2, 29	94
444	Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease. <b>2015</b> , 16, 18185-223	48
443	Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. <b>2015</b> , 13, 26-36	153
442	Antioxidant strategies in the management of diabetic neuropathy. <b>2015</b> , 2015, 515042	85
441	Role of Vitamin D deficiency in extraskeletal complications: predictor of health outcome or marker of health status?. <b>2015</b> , 2015, 563403	25
440	The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. <b>2015</b> , 22, 1515-26	63
439	Dietary Supplements in Older Adults. <b>2015</b> , 375-424	
438	High-Risk Nutrients in the Aging Population. <b>2015</b> , 335-353	2
437	Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. <b>2015</b> , 66, 2886-2898	33
436	Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability. <b>2015</b> , 239, 232-9	12
435	Supplementation with vitamin E alone is associated with reduced myocardial infarction: a meta-analysis. <b>2015</b> , 25, 354-63	40
434	Targeted antioxidant treatment decreases cardiac alternans associated with chronic myocardial infarction. <b>2015</b> , 8, 165-73	10
433	Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. <b>2015</b> , 35, 206-15	29
432	Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations. <b>2015</b> , 68, 1046-58	110

431	Antioxidants in Translational Medicine. <b>2015</b> , 23, 1130-43	160
430	Dietary fruits and vegetables and cardiovascular diseases risk. <b>2017</b> , 57, 1950-1962	108
429	c-Jun N-terminal kinase attenuates TNFBignaling by reducing Nox1-dependent endosomal ROS production in vascular smooth muscle cells. <b>2015</b> , 86, 219-27	17
428	Mitochondria as key targets of cardioprotection in cardiac ischemic disease: role of thyroid hormone triiodothyronine. <b>2015</b> , 16, 6312-36	40
427	Are reactive oxygen species still the basis for diabetic complications?. <b>2015</b> , 129, 199-216	59
426	Epigallocatechin-3-gallate activates diacylglycerol kinase alpha via a 67 kDa laminin receptor: A possibility of galloylated catechins as functional food to prevent and/or improve diabetic renal dysfunctions. <b>2015</b> , 15, 561-569	10
425	Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <b>2015</b> , 12, 4	13
424	Blockage of ROS and NF- <b>B</b> -mediated inflammation by a new chalcone L6H9 protects cardiomyocytes from hyperglycemia-induced injuries. <b>2015</b> , 1852, 1230-41	54
423	Impact of eNOS-Dependent Oxidative Stress on Endothelial Function and Neointima Formation. <b>2015</b> , 23, 711-23	20
422	Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. <b>2015</b> , 26, 176-83	64
421	Pharmacology and Clinical Drug Candidates in Redox Medicine. <b>2015</b> , 23, 1113-29	59
420	Vitamin therapy after heart transplantation. <b>2015</b> , 13, 1071-4	2
419	Fruits and Vegetables Get a Golden Halo Once Again: Is There More to the Story?. <i>Circulation</i> , <b>2015</b> , 132, 1946-8	2
418	Statin therapy and plasma vitamin E concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. <b>2015</b> , 243, 579-88	4
417	Multivitamin use and cardiovascular disease in a prospective study of women. <b>2015</b> , 101, 144-52	23
416	The progress of inflammation and oxidative stress in patients with chronic kidney disease. <b>2015</b> , 37, 45-9	44
415	Handbook of Clinical Nutrition and Aging. 2015,	4
414	Autophagy and mitophagy in diabetic cardiomyopathy. <b>2015</b> , 1852, 252-61	126

413	Novel therapeutic approaches for diabetic nephropathy and retinopathy. 2015, 98, 39-44	25
412	Cardiac NO signalling in the metabolic syndrome. <b>2015</b> , 172, 1415-33	44
411	Comprehensive Management of High Risk Cardiovascular Patients. 2016,	1
410	Vitamin E supplementation for adults with diabetes mellitus. 2016,	
409	Vitamins, Are They Safe?. <b>2016</b> , 6, 467-477	31
408	Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease. <b>2016</b> , 2016, 9152732	194
407	Metabolic Remodeling in the Development of Heart Failure. <b>2016</b> , 169-181	
406	Antioxidant Supplementation in the Treatment of Aging-Associated Diseases. <b>2016</b> , 7, 24	103
405	The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications. <b>2016</b> , 4,	40
404	A Speculative Pharmaceutical Cocktail to Treat Spinal Cord Injury. <b>2016</b> , 95, e108-10	4
404	A Speculative Pharmaceutical Cocktail to Treat Spinal Cord Injury. <b>2016</b> , 95, e108-10  Nutraceutical therapies for atherosclerosis. <b>2016</b> , 13, 513-32	106
403	Nutraceutical therapies for atherosclerosis. <b>2016</b> , 13, 513-32	106
403	Nutraceutical therapies for atherosclerosis. <b>2016</b> , 13, 513-32  Mitochondrial Therapies in Heart Failure. <b>2017</b> , 243, 491-514	106
403	Nutraceutical therapies for atherosclerosis. 2016, 13, 513-32  Mitochondrial Therapies in Heart Failure. 2017, 243, 491-514  Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome. 2016, 25, 874-80	106 13 30
403 402 401 400	Nutraceutical therapies for atherosclerosis. 2016, 13, 513-32  Mitochondrial Therapies in Heart Failure. 2017, 243, 491-514  Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome. 2016, 25, 874-80  Dietary supplements and disease prevention - a global overview. 2016, 12, 407-20	106 13 30 100
403 402 401 400 399	Nutraceutical therapies for atherosclerosis. 2016, 13, 513-32  Mitochondrial Therapies in Heart Failure. 2017, 243, 491-514  Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome. 2016, 25, 874-80  Dietary supplements and disease prevention - a global overview. 2016, 12, 407-20  Reviews of Physiology, Biochemistry and Pharmacology Vol. 170. 2016,  Can Outcomes be Improved in Dialysis Patients by Optimizing Trace Mineral, Micronutrient, and	106 13 30 100

395	Evaluation of Brain Redox Status and Its Association with Cognitive Dysfunction in Diabetic Animal Models by Redox Molecular Imaging (ReMI). <b>2016</b> , 136, 1081-6	1
394	Underpinning Science. <b>2016</b> , 131-159	
393	Prescribing safely: Top 10 tips for non-medical prescribers. <b>2016</b> , 14, 408-413	1
392	Compartment-specific Control of Reactive Oxygen Species Scavenging by Antioxidant Pathway Enzymes. <b>2016</b> , 291, 11185-97	68
391	Role of PGC-1 <del>H</del> n Vascular Regulation: Implications for Atherosclerosis. <b>2016</b> , 36, 1467-74	44
390	PrimĒpr⊠ention: Noch mehr Patienten mit Statinen behandeln?. <b>2016</b> , 16, 9-12	
389	To Supplement or Not: A Role for Antioxidant Vitamins in the Management of Heart Failure?. <b>2016</b> , 129, 767-8	5
388	Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. <b>2016</b> , 26, 285-92	68
387	Highly Cross-Linked UHMWPE Doped with Vitamin E. <b>2016</b> , 307-325	6
386	The effects of high-dose vitamin E supplementation on biomarkers of kidney înjury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial. <b>2016</b> , 10, 922-929	30
385	Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). <b>2016</b> , 103, 283-9	30
384	Role of phytochemicals in the management of metabolic syndrome. <b>2016</b> , 23, 1134-44	90
383	Cardiac Response to Oxidative Stress Induced by Mitochondrial Dysfunction. <b>2016</b> , 170, 101-27	11
382	Mitochondrial quality control in the diabetic heart. <b>2016</b> , 95, 57-69	44
381	Therapeutic Strategies Harnessing Oxidative Stress to Treat Stroke. <b>2017</b> , 113-133	
380	Redox modification of caveolar proteins in the cardiovascular system- role in cellular signalling and disease. <b>2017</b> , 109, 61-74	22
379	Dendritic cells and isolevuglandins in immunity, inflammation, and hypertension. <b>2017</b> , 312, H368-H374	24
378	Antioxidant therapy for management of oxidative stress induced hypertension. <b>2017</b> , 51, 428-438	51

### (2017-2017)

377	The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling. <b>2017</b> , 108, 585-594	28
376	Neuronutrition: An Emerging Concept. <b>2017</b> , 155-206	
375	Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes. <b>2017</b> , 17, 42	17
374	Nutrition in Neurologic Disorders. 2017,	1
373	Urinary F-isoprostanes and the risk of hypertension. <b>2017</b> , 27, 391-396	7
372	The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. <b>2017</b> , 76, 203-212	51
371	Heart Failure. <b>2017</b> ,	4
370	A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition. <b>2017</b> , 22, 825-842	19
369	Hydrogen Peroxide Triggers a Dual Signaling Axis To Selectively Suppress Activated Human T Lymphocyte Migration. <b>2017</b> , 198, 3679-3689	9
368	An increasing problem in publication ethics: Publication bias and editors' role in avoiding it. <b>2017</b> , 20, 171-178	26
367	DNA damage-dependent mechanisms of ageing and disease in the macro- and microvasculature. <b>2017</b> , 816, 116-128	16
366	Studies on Atherosclerosis. <b>2017</b> ,	3
365	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <b>2017</b> , 14, 238-250	322
364	Anti-inflammatory drugs as promising cardiovascular treatments. <b>2017</b> , 15, 109-125	13
363	Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors. <b>2017</b> , 38, 2233-2236	
362	Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <b>2017</b> , 52 Suppl 1, S45-S74	7
361	Vitamins for Cardiovascular Diseases: Is the Expense Justified?. <b>2017</b> , 25, 298-308	3
360	Les suppl <del>li</del> hentations vitaminiques systfhatiques : ont-elles une place dans la pr¶ention des maladies chroniques ?. <b>2017</b> , 11, 246-257	4

359	Ellagic Acid Reduces High Glucose-Induced Vascular Oxidative Stress Through ERK1/2/NOX4 Signaling Pathway. <b>2017</b> , 44, 1174-1187		36
358	High-performance thin-layer chromatographic methods in the evaluation of the antioxidant and anti-hyperglycemic activity of Myrmecodia platytyrea as a promising opportunity in diabetes treatment. <b>2017</b> , 1530, 192-196		9
357	Genetic Deletion of NADPH Oxidase 1 Rescues Microvascular Function in Mice With Metabolic Disease. <b>2017</b> , 121, 502-511		20
356	Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. <b>2017</b> , 70, 230-251		164
355	Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 338-349	2.8	50
354	Nonalcoholic fatty liver disease: implications for cardiovascular risk. <b>2017</b> , 6, 62-72		7
353	Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases. <b>2017</b> , 26, 700-717		26
352	Cautionary tales in the interpretation of observational studies of effects of clinical interventions. <b>2017</b> , 47, 144-157		8
351	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. <b>2017</b> , 17, 83-95		7
350	Mitochondrial dysfunction and its impact on diabetic heart. <b>2017</b> , 1863, 1098-1105		36
349	Targeting Complications of Diabetes with Antioxidants. <b>2017</b> , 397-445		1
348	Diet and Heart Disease. <b>2017</b> , 305-312		
347	The Role of Diet in the Prevention and Treatment of Cardiovascular Disease. 2017, 595-623		3
346	Oxidative Stress-Responsive Apoptosis Inducing Protein (ORAIP) Plays a Critical Role in High Glucose-Induced Apoptosis in Rat Cardiac Myocytes and Murine Pancreatic Ecells. <b>2017</b> , 6,		17
345	Reduced Dietary Selenium Impairs Vascular Function by Increasing Oxidative Stress in Sprague-Dawley Rat Aortas. <b>2017</b> , 14,		13
344	Oxidative Stress in Hemodialysis Patients: A Review of the Literature. <b>2017</b> , 2017, 3081856		109
343	Functional and Biological Potential of Bioactive Compounds in Foods for the Dietary Treatment of Type 2 Diabetes Mellitus. <b>2017</b> ,		5
342	Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty. <b>2017</b> , 13, 558-567		10

341	Analysis, Presentation, and Interpretation of Dietary Data. 2017, 167-184		2
340	Free-radicals and advanced chemistries involved in cell membrane organization influence oxygen diffusion and pathology treatment. <b>2017</b> , 4, 240-283		18
339	PROTECTIVE ROLE OF CARNITINE SYNERGIZED WITH VITAMIN E AGAINST ISOPROTERENOL INDUCED CARDIAC INFARCTION IN RATS. <b>2017</b> , 14, 25-32		3
338	Vitamins in Heart Failure: Friend or Enemy?. <b>2017</b> , 23, 3731-3742		8
337	Antioxidant treatment in peripheral artery disease: the rationale is there, but what about clinical results?. <b>2018</b> , 39, 53-59		5
336	Deficiency of aldose reductase exacerbates early pressure overload-induced cardiac dysfunction and autophagy in mice. <b>2018</b> , 118, 183-192		15
335	Effects of dietary RRR £ocopherol vs all-racemic £ocopherol on health outcomes. <b>2018</b> , 76, 141-153		28
334	Mechanisms Involved in Premature Aging in the Heart-Is There an Implication for Cardiac Surgery?. <b>2018</b> , 66, 31-41		3
333	Coronary Artery Disease. 2018, 253-263.e2		
332	Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). <b>2018</b> , 195, 70-77		1
331	Vitamin E in Hemodialysis Patients. 2018,		
330	50 Herz- und Gef¶rankheiten. <b>2018</b> ,		
329	Untargeted Metabolic Profiling Cell-Based Approach of Pulmonary Artery Smooth Muscle Cells in Response to High Glucose and the Effect of the Antioxidant Vitamins D and E. <b>2018</b> , 8,		5
328	Oxidative Stress and Heart Failure. <b>2018</b> , 230-251		3
327	Oxidants and Endothelial Dysfunction. 2018, 252-281		1
326	Hypoxia and Ischemia Signaling. <b>2018</b> , 352-361		
325	Optimal medical treatment of hypertension in patients with coronary artery disease. <b>2018</b> , 16, 815-823		1
324	Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping. <i>Frontiers in Cardiovascular Medicine</i> , <b>2018</b> , 5, 141	5.4	7

323	Anti-atherogenic properties of vitamin E, aspirin, and their combination. <b>2018</b> , 13, e0206315	5
322	Control of Blood Pressure and Cardiovascular Outcomes in Type 2 Diabetes. <b>2018</b> , 13, 304-323	5
321	Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?. <i>Current Atherosclerosis Reports</i> , <b>2018</b> , 20, 36	22
320	Nrf2 Deficiency Unmasks the Significance of Nitric Oxide Synthase Activity for Cardioprotection. <b>2018</b> , 2018, 8309698	20
319	Anti-Inflammatory Treatment. 2018, 237-271	
318	Anti-Oxidant Treatment. 2018, 273-300	1
317	Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy. 2018, 2018, 1875870	132
316	Insights on Localized and Systemic Delivery of Redox-Based Therapeutics. <b>2018</b> , 2018, 2468457	7
315	Natural approaches in metabolic syndrome management. <b>2018</b> , 14, 422-441	83
314	HPTLC - Bioautographic methods for selective detection of the antioxidant and Hamylase inhibitory activity in plant extracts. <b>2018</b> , 5, 797-802	9
313	Inflammation, not Cholesterol, Is a Cause of Chronic Disease. <b>2018</b> , 10,	142
312	Suppression of DNA/RNA and protein oxidation by dietary supplement which contains plant extracts and vitamins: a randomized, double-blind, placebo-controlled trial. <b>2018</b> , 17, 187	9
311	Haptoglobin and haptoglobin genotypes in diabetes: A silver bullet to identify the responders to antioxidant therapy?. <b>2018</b> , 25, 1498-1501	2
310	Evidence Collection and Evaluation for the Development of Dietary Guidelines and Public Policy on Nutrition. <b>2019</b> , 39, 227-247	10
309	The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway. <b>2019</b> , 2019, 5470470	17
308	Oxidative Stress Reduction (Prong-3). <b>2019</b> , 139-254	
307	Antioxidants and Atherosclerosis: Mechanistic Aspects. <b>2019</b> , 9,	74
306	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. <b>2019</b> , 42, 1760-1768	15

305	Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable. 2019, 20,		11
304	Towards a characterization of apparent contradictions in the biomedical literature using context analysis. <b>2019</b> , 98, 103275		8
303	Circulating Vitamin E Levels and Risk of Coronary Artery Disease and Myocardial Infarction: A Mendelian Randomization Study. <b>2019</b> , 11,		25
302	Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure Report from the 2018 National Heart, Lung, and Blood Institute Workshop. <i>Circulation</i> , <b>2019</b> , 140, 1205-1216	16.7	43
301	Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature. <b>2019</b> , 31, 31-47		О
300	Pain reduction and improved vascular health associated with daily consumption of an anti-inflammatory dietary supplement blend. <b>2019</b> , 12, 1497-1508		3
299	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <b>2019</b> , 42, 1512-1520		41
298	The Relationship between Whole Grain Intake and Body Weight: Results of Meta-Analyses of Observational Studies and Randomized Controlled Trials. <b>2019</b> , 11,		25
297	The Philosophy of Evidence-Based Principles and Practice in Nutrition. <b>2019</b> , 3, 189-199		11
296	Last Nail in the Coffin for Sugar-Sweetened Beverages. <i>Circulation</i> , <b>2019</b> , 139, 2126-2128	16.7	4
296 295	Last Nail in the Coffin for Sugar-Sweetened Beverages. <i>Circulation</i> , <b>2019</b> , 139, 2126-2128  Clinical Cardiovascular Disease Trials: The Vitamin E Case. <b>2019</b> , 273-282	16.7	4
		16.7	4
295	Clinical Cardiovascular Disease Trials: The Vitamin E Case. <b>2019</b> , 273-282  Haptoglobin Genotype and a Promising Pharmacogenomic Approach to Prevent Diabetic	16.7	2
295 294	Clinical Cardiovascular Disease Trials: The Vitamin E Case. <b>2019</b> , 273-282  Haptoglobin Genotype and a Promising Pharmacogenomic Approach to Prevent Diabetic Atherothrombosis with Vitamin E Supplementation. <b>2019</b> , 283-294	16.7	
295 294 293	Clinical Cardiovascular Disease Trials: The Vitamin E Case. <b>2019</b> , 273-282  Haptoglobin Genotype and a Promising Pharmacogenomic Approach to Prevent Diabetic Atherothrombosis with Vitamin E Supplementation. <b>2019</b> , 283-294  History of Vitamin E Research. <b>2019</b> , 7-18	16.7	2
295 294 293 292	Clinical Cardiovascular Disease Trials: The Vitamin E Case. 2019, 273-282  Haptoglobin Genotype and a Promising Pharmacogenomic Approach to Prevent Diabetic Atherothrombosis with Vitamin E Supplementation. 2019, 283-294  History of Vitamin E Research. 2019, 7-18  Nonalcoholic Fatty Liver Disease and 'the 'Heart: JACC State-of-the-Art Review. 2019, 73, 948-963  Implications of product withdrawal on a post-approval pragmatic trial: The VOLUME study	16.7	2
295 294 293 292 291	Clinical Cardiovascular Disease Trials: The Vitamin E Case. 2019, 273-282  Haptoglobin Genotype and a Promising Pharmacogenomic Approach to Prevent Diabetic Atherothrombosis with Vitamin E Supplementation. 2019, 283-294  History of Vitamin E Research. 2019, 7-18  Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. 2019, 73, 948-963  Implications of product withdrawal on a post-approval pragmatic trial: The VOLUME study experience. 2019, 16, 100477	16.7	2 135

287 Cardiovascular Disease in Chronic Kidney Disease. **2019**, 176-193.e9

286	Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature. <b>2019</b> , 31, 31-47	1
285	Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety. <b>2019</b> , 19, 1-10	1
284	Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism. <b>2020</b> , 1867, 118471	25
283	Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. 2020, 148, 60-69	28
282	Mitochondrially-targeted treatment strategies. <b>2020</b> , 71, 100836	14
281	[Primary prevention of coronary heart disease : Evidence-based drug treatment]. <b>2020</b> , 45, 39-49	
280	In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin. <b>2020</b> , 138, 165-174	7
279	Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. <b>2020</b> , 112, 1642-1652	22
278	Environment-wide association study on childhood obesity in the U.S. <b>2020</b> , 191, 110109	2
277	Mendelian randomization and pleiotropy analysis. <b>2021</b> , 9, 122-132	5
276	Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. <b>2020</b> , 9, e017165	6
275	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <b>2020</b> , 76, 580-589	22
274	Role of TSPO/VDAC1 Upregulation and Matrix Metalloproteinase-2 Localization in the Dysfunctional Myocardium of Hyperglycaemic Rats. <b>2020</b> , 21,	4
273	Effect of vitamin E on low density lipoprotein oxidation at lysosomal pH. <b>2020</b> , 54, 574-584	2
272	The Antihypertensive Effect of Quercetin in Young Spontaneously Hypertensive Rats; Role of Arachidonic Acid Metabolism. <b>2020</b> , 21,	10
271	Demystifying Oxidative Stress. <b>2021</b> , 264, 3-26	1
270	Indian guidelines on hypertension-IV (2019). <b>2020</b> , 34, 745-758	24

# (2021-2020)

269	Quantification of fat-soluble vitamins and their metabolites in biological matrices: an updated review. <b>2020</b> , 12, 625-640	2
268	Basic Mechanisms of Diabetic Heart Disease. <b>2020</b> , 126, 1501-1525	89
267	Ginkgo Biloba: Plant-Based Proarrhythmic Potential?. <b>2020</b> , 2, 968-972	1
266	Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. <b>2020</b> , 157, 15-37	46
265	Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. <b>2020</b> , 52, 619-636	4
264	Vitamin C. <b>2020</b> , 241-262	1
263	Full Issue PDF. <b>2020</b> , 2, I-CXLV	
262	Pharmacological interventions for heart failure in people with chronic kidney disease. <b>2020</b> , 2, CD012466	3
261	Comparative efficacy of vitamin supplements on prevention of major cardiovascular disease: Systematic review with network meta-analysis. <b>2020</b> , 39, 101142	7
260	Myocardial injection of a thermoresponsive hydrogel with reactive oxygen species scavenger properties improves border zone contractility. <b>2020</b> , 108, 1736-1746	4
259	Vitamin E Intake Is Associated with Lower Brain Volume in Haptoglobin 1-1 Elderly with Type 2 Diabetes. <b>2020</b> , 74, 649-658	1
258	Dietary or supplemental intake of antioxidants and the risk of mortality in older people: A systematic review. <b>2021</b> , 78, 24-40	2
257	Effects of vitamin E on stroke: a systematic review with meta-analysis and trial sequential analysis. <b>2021</b> , 6, 109-120	5
256	Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go?. <b>2021</b> , 65, e2000097	15
255	KLF5 Is Induced by FOXO1 and Causes Oxidative Stress and Diabetic Cardiomyopathy. <b>2021</b> , 128, 335-357	14
254	Dietary and supplemental antioxidant intake and risk of major adverse cardiovascular events in older men: The concord health and ageing in men project. <b>2021</b> , 31, 1102-1112	O
253	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <b>2021</b> , 38, e14459	1
252	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <b>2021</b> , 44, 595-603	1

251	Salmon food matrix influences digestion and bioavailability of long-chain omega-3 polyunsaturated fatty acids. <b>2021</b> , 12, 6588-6602	3
250	Randomized Controlled Trials 1: Design. <b>2021</b> , 2249, 193-211	
249	Role of Dietary Nutrition, Vitamins, Nutrients, and Supplements in Cardiovascular Health. 2021, 1-27	1
248	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <b>2021</b> , 16, e0244402	8
247	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <b>2021</b> , 42, 658-690	10
246	Antioxidant vitamins and their effect on immune system. <b>2021</b> , 1853, 012065	3
245	Diet-derived antioxidants do not decrease the risk of ischemic stroke: a Mendelian Randomization Study in over 1 million participants.	О
244	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. 2021,	4
243	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. 2021, 10,	2
242	Diabetic fibrosis. <b>2021</b> , 1867, 166044	20
241	The Associations of Perceived and Oxidative Stress with Hypertension in a Cohort of Police Officers. <b>2021</b> , 14, 1783-1797	1
240	Regulation of Cardiac PKA Signaling by cAMP and Oxidants. <i>Antioxidants</i> , <b>2021</b> , 10, 7.1	2
239	Essential Micronutrients: Vitamins and Essential Fatty Acids. 1-83	
238	The effects of vitamin E supplementation on malondialdehyde as a biomarker of oxidative stress in haemodialysis patients: a systematic review and meta-analysis. <b>2021</b> , 22, 126	10
237	The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. <b>2021</b> , 167, 66-80	5
236	Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases. <b>2021</b> , 169, 446-477	16
235	Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. 2021, 169, 317-342	16
234	Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function Decline and with CYP4F2 Missense Variation.	

233	Particulate matter air pollutants and cardiovascular disease: Strategies for intervention. <b>2021</b> , 223, 107890	9
232	Ferroptosis: the potential value target in atherosclerosis. <b>2021</b> , 12, 782	12
231	Vitamins E and C do not effectively inhibit low density lipoprotein oxidation by ferritin at lysosomal pH. <b>2021</b> , 1-10	
230	Evaluating Concordance of Bodies of Evidence From Randomized Controlled Trials, Dietary Intake and Biomarkers of Intake in Cohort Studies: A Meta-Epidemiological Study. <b>2021</b> ,	3
229	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. <b>2021</b> , 176, 113904	5
228	Human iPSC-Based Model Reveals NOX4 as Therapeutic Target in Duchenne Cardiomyopathy.	О
227	Evaluating agreement between bodies of evidence from randomised controlled trials and cohort studies in nutrition research: meta-epidemiological study. <b>2021</b> , 374, n1864	4
226	Salt Sensitivity of Blood Pressure in Blacks and Women: A Role of Inflammation, Oxidative Stress, and Epithelial Na Channel. <b>2021</b> , 35, 1477-1493	О
225	Pathogenesis of Diabetic Microvascular Complications.	1
224	Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. <b>2021</b> , 35, 2945-2967	12
223	Pharmacological Compounds with Antioxidant Activity. <b>2006</b> , 167-194	2
222	ACE inhibitors and angiotensin II receptor antagonists. <b>2005</b> , 407-42	25
221	Oxidative Stress in Arterial Hypertension: Oxidative Stress and Hypertension. 2008, 51-78	1
220	Randomized controlled trials 1: Design. <b>2015</b> , 1281, 159-75	1
219	Antioxidant Vitamin Supplementation and Cardiovascular Disease. 2005, 245-277	3
218	Fatty Acids, Cell Signaling, and Cardiovascular Risk. <b>2007</b> , 187-203	1
217	Microvascular Changes in the Diabetic Foot. <b>2006</b> , 131-145	2
216	The design of randomized controlled trials. <b>2009</b> , 473, 95-111	1

215	Oxidative Stress in Type 2 Diabetes Mellitus. <b>2008</b> , 191-211	5
214	Antioxidant and B-vitamins and Atherosclerosis. <b>2010</b> , 285-323	1
213	Novel Synthetic Antioxidants and Nitrated Lipids: From Physiology to Therapeutic Implications. <b>2010</b> , 473-498	1
212	Oxidative Stress in Vascular Disease. <b>2010</b> , 211-235	2
211	Cardiovascular Disease and Insulin Resistance. <b>2007</b> , 2803-2818	2
210	Synthetic Antioxidants. <b>2020</b> , 543-551	1
209	Mitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders. 2017, 982, 621-646	12
208	Reactive Oxygen Species in Hypertension and Atherosclerosis. <b>2014</b> , 1239-1254	1
207	Chapter 11 Tocochromanols: Biological Function and Recent Advances to Engineer Plastidial Biochemistry for Enhanced Oil Seed Vitamin E Levels. <b>2010</b> , 155-170	1
206	The Role of Vitamin E Forms in Cancer Prevention and Therapy latudies in Human Intervention Trials and Animal Models. <b>2012</b> , 323-354	4
205	Plasma 8-Isoprostane as a Biomarker and Applications to Cardiovascular Disease. <b>2015</b> , 1-22	1
204	The Antioxidant Hypothesis. <b>2000</b> , 47-56	1
203	Improving the trustworthiness of findings from nutrition evidence syntheses: assessing risk of bias and rating the certainty of evidence. <b>2021</b> , 60, 2893-2903	15
202	Effects of Astaxanthin Supplementation on Oxidative Stress. <b>2020</b> , 90, 179-194	15
201	Serum homocysteine and coronary heart disease. <b>2005</b> , 239-250	1
200	Prevention of coronary heart disease: findings from the Nurses[Health Study and Health Professionals[Follow-up Study. <b>2005</b> , 654-668	1
199	The secondary prevention of cardiovascular disease. <b>2005</b> , 769-791	1
198	Effects of alpha-tocopherol on ox-LDL-mediated degradation of IkappaB and apoptosis in cultured human coronary artery endothelial cells. <b>2000</b> , 36, 297-301	26

# (2012-2006)

197	The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. <b>2006</b> , 13, 341-347		22
196	Oxidant Stress as a Marker for Cardiovascular Events. <i>Circulation</i> , <b>2001</b> , 104, 2638-2640	16.7	91
195	Looking for the Pony in the HERS Data. Circulation, 2002, 105, 902-903	16.7	10
194	Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. <i>Circulation</i> , <b>2008</b> , 118, 1347-57	16.7	76
193	Oxygen, oxidative stress, hypoxia, and heart failure. <b>2005</b> , 115, 500-8		1056
192	Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. 2013, 123, 1262-74		179
191	Vasculoprotective Effects of Olive Oil. 2003,		2
190	Nutrition and Health Implications of Vitamin E. <b>2004</b> , 39-88		11
189	Supercritical Fluid Extraction of Specialty Oils. 2007, 51-101		3
188	Vitamin E. <b>2003</b> ,		3
187	277. <b>2013</b> , 229-277		1
186	The role of oxidative stress and antioxidants in diabetic complications. <b>2012</b> , 12, 5-18		315
185	Results of observational studies: analysis of findings from the Nurses' Health Study. <b>2014</b> , 9, e110403		15
184	The Cardioprotective Effect of Vitamin E (Alpha-Tocopherol) Is Strongly Related to Age and Gender in Mice. <b>2015</b> , 10, e0137405		11
183	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. <b>2015</b> , 10, e0139975		9
182	GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species. <b>2019</b> , 1, R1-R11		6
181	The potential and limits of functional foods in preventing cardiovascular disease. <b>2004</b> , 1-9		4

179	Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetesa cross-sectional study. <b>2005</b> , 2, 157-64	13
178	Platelet Oxidative Stress and its Relationship with Cardiovascular Diseases in Type 2 Diabetes Mellitus Patients. <b>2019</b> , 26, 4145-4165	11
177	Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?. <b>2019</b> , 15, 55-63	42
176	The Oxidative State of LDL is the Major Determinant of Anti/Prooxidant Effect of Coffee on Cu Catalysed Peroxidation. <b>2011</b> , 5, 1-8	6
175	Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. <b>2010</b> , 4, 240-56	66
174	Behavioral Factors Associated with Disease, Injury, and Death among Men: Evidence and Implications for Prevention. <b>2002</b> , 1, 281-342	10
173	The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes. <b>2020</b> , 22,	1
172	Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. <b>2013</b> , 5, 2969-3004	125
171	Mechanism of Developing Diabetic Vascular Complication by Oxidative Stress. 2006, 21, 448	7
170	Dietary vitamin intake and risk of metabolic syndrome among centenarians in China. <b>2021</b> , 21, 105	3
169	Atherosclerosis: A Link between Lipid Intake and Protein Tyrosine Nitration. 2008, 2, LPI.S1030	6
168	The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. <b>2007</b> , 27, 409-14	15
167	The Association between Dietary Antioxidant Quality Score and Cardiorespiratory Fitness in Iranian Adults: a Cross-Sectional Study. <b>2020</b> , 9, 171-181	1
166	Effectiveness of Some Vitamins in the Prevention of Cardiovascular Disease: A Narrative Review. <b>2021</b> , 12, 729255	7
165	????????????????NADH/NADPH?????????? : 1.?????????(?64? ??????????). <b>2000</b> , 8, 211-216	
164	Prevention. <b>2000</b> , 15, 343-7	
163	Koronare Herzerkrankung ြSchdigung durch freie Radikale, Schutz durch Antioxidantien und die Rolle von Homozystein. <b>2001</b> , 110-122	
162	Medical Nutrition Therapy for Diabetes. <b>2001</b> , 167-193	

Anti-Atherogenic Properties of Heme Oxygenase. 2002, 293-301 161 Coronary Artery Disease and Endothelial Function. 2002, 887-912 160 Atherosclerotic Lesions: Vulnerability. 2002, 327-339 159 Beyond \_-Tocopherol. 2002, 158 Nutrition and Cardiovascular Health. 2002, 23-43 157 References. Circulation, 2002, 106, 3373-3421 16.7 1 156 Is There a Role for Vitamin E in the Prevention of Atherosclerosis?. 2003, 155 What are the Effects of Dietary Supplements (Selenium and Vitamin E) or Aspirin/NSAIDs on 154 Prostate Cancer?. 2003, 193-205 Prospective Vitamin E Clinical Trials. 2003, 153 The Newer Coronary Risk Factors. 2003, 193-211 152 Seminal Changes in the Management of the Acute Coronary Event: Current Concepts. 2003, 12, 73-76 151 Vitamin E in Disease Prevention and Therapy. 2003, 150 Potential Adverse Effects of Vitamins C and E. 2003, 149 Retinol, Beta-Carotene, and Alpha-Tocopherol in Heart Disease. 2003, 148 Dietary Prevention of CHD. 2003, 147 146 Micronutrients and Cardiovascular Disease. 2003, Der ganze Patient. 2004, 375-405 145 Gender and Its Impact on Risk Factors for Cardiovascular Disease. 2004, 193-214 144

143	Vitamine und Neuropathieprparate. <b>2004</b> , 846-862
142	Vitamine und Neuropathieprparate. <b>2004</b> , 899-912
141	Dietary Supplements for Health Maintenance and Risk Factor Reduction. <b>2004</b> , 127-189
140	Chronic Heart Failure. <b>2004</b> , 437-453
139	Dietary Therapy of Diabetes Mellitus. <b>2004</b> , 529-542
138	Bedside Platelet Monitoring. <b>2004</b> , 495-520
137	New strategy of cardiovascular disease by redox regulation. <b>2005</b> , 16, 365-371
136	Potential Benefits of Preventive Nutrition Strategies. <b>2005</b> , 713-733
135	Oxidized Products of Cholesterol. <b>2005</b> ,
134	Probleme mit Vitaminprparaten. <b>2005</b> , 26,
133	Antioxidants and cardiovascular disease. <b>2005</b> , 220-238
132	Vitamin E. <b>2005</b> , 183-200
131	The Vascular Biology of Atherosclerosis. <b>2005</b> , 61-84
130	Is er in het kader van secundaire preventie een reden voor het voorschrijven van vitamine E?. <b>2006</b> , 770-771
129	Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss. <b>2006</b> , 158-165
128	Lipoprotein-Associated Phospholipase A2 and Other Lipid-Related Biomarkers in Cardiovascular Disease. <b>2006</b> , 519-542
127	Medical Nutrition Therapy For Patients With Type-2 Diabetes. <b>2006</b> , 81-104
126	Anticancer Supplements and Botanicals to Prevent and Treat Cancer: Does Any Clinical Evidence Exist?. <b>2006</b> , 2, 22-35

#### (2010-2006)

Vascular Dysfunction and Obesity. 2006, 93-120 125 Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease. 2006, 79-146 124 Chronic Stable Angina. 2007, 290-313 123 Dysfonctionnement vasculaire dans les dbordres mbaboliques : evaluation de quelques essais 122 thfapeutiques. 2007, 191, 475-493 Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease. 2007, 79-145 121 The Role of Oxidative Stress in Diseases Associated with Overweight and Obesity. 2007, 33-46 120 Menopause and Midlife. 2007, 119 Interventional Trials of Antioxidants. 2008, 25-50 118 Antioxidant Vitamins No Benefit for CVD Prevention. 2008, 101, 339-340 117 Tocopherol and Tocotrienols. 2008, 223-235 116 Literatur. 2009, 425-429 115 Lycopene and Cardiovascular Diseases. 2009, 243-271 114 Public Health Benefits of Preventive Nutrition. 2010, 3-22 113 Dietary Therapy of Diabetes Mellitus. 2010, 677-686 112 The Coronary Circulation. 2010, 903-917 111 Mechanisms of Redox Signaling in Cardiovascular Disease. 2010, 43-60 Clinical Trial Design in Heart Failure. 2010, 570-593 109 Redox-Related Genetic Markers of Cardiovascular Diseases. 2010, 187-209 108

107	Oxidative Risk Factors for Cardiovascular Disease in Women. <b>2010</b> , 443-453
106	Oxidative Stress and Redox Signalling in Cardiac Remodelling. <b>2010</b> , 405-424
105	Carbamylated Low-density Lipoprotein and Adhesion Molecules. <b>2010</b> , 375-391
104	Mega-trial of vitamin E yields negative result. <b>2001</b> , 6, 129-130
103	Scientific Rationale of Current Trends in Clinical Studies of Micronutrients for Prevention of Chronic Diseases. <b>2010</b> , 23-34
102	Newer Coronary Risk Factors. <b>2011</b> , 113-139
101	Nutrition. <b>2011</b> , 47-65
100	Bioactive Nutritional Supplements for Chronic Kidney Disease: Potential Cost Benefits. <b>2011</b> , 301-314
99	Hypertension. <b>2011</b> , 121-142
98	Vitamins, herbs, supplements, and anti-inflammatories. <b>2011</b> , 193-198
97	Alternative Therapies for Chronic Refractory Coronary Artery Disease. <b>2012</b> , 125-137
96	Endothelium Biology. <b>2012</b> , 219-237
95	Coronary Artery Disease. <b>2012</b> , 227-236.e2
94	Encyclopedia of Sustainability Science and Technology. <b>2012</b> , 3655-3674
93	The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies. 640-654
92	Tocotrienols and Vascular Effects. <b>2012</b> , 267-278
91	The Endothelium, Cardiovascular Disease, and Therapy. 409-467

#### (2019-2013)

Reducing Oxidative Stress and Manipulating Molecular Signaling Events Using Resveratrol as a 89 Therapy for Pathological Cardiac Hypertrophy. 2013, 227-254 88 Vitamines. 2013, 362-393 Study on the Correlation between the Nutrient Intakes and Clinical Indices of Type 2 Diabetes 87 5 Patients. 2013, 26, 909-918 Aging-Related Changes in Cell Death and Cell Survival Pathways and Implications for Heart Failure 86 Therapy. **2014**, 339-349 Targeting Superoxide Generation in Cardiovascular Diseases. 2014, 1479-1496 85 Overview of Oxidative Stress and Cardiovascular Disease. 2014, 719-764 84 83 Oxidative Stress in Diabetes Mellitus and Possible Interventions. 2014, 237-261 Targeting Oxidative Stress in Heart Failure. 2014, 993-1019 82 Natural products for the management of type 2 diabetes mellitus and comorbid conditions. 2014, 81 20, 58-72 80 Public Health Benefits of Preventive Nutrition: Global Perspective. 2015, 25-46 Functional Foods. 2015, 37-48 79 78 Plasma 8-Isoprostane as a Biomarker and Applications to Cardiovascular Disease. 2016, 467-488 Basic Facts about Antioxidants. 2016, 27-38 77 ROS in Atherosclerotic Renovascular Disease. 2017, 19-45 76 Integrated Approach to Coronary Artery Disease. 2017, 203-221 75  $\circ$ 4 Functional Foods. **2017**, 37-48 74 Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Ο 73 Dietary Antioxidants in Mitigating Oxidative Stress in Cardiovascular Diseases. 2019, 83-139 72

71	Key Cellular Effectors in ROS-Mediated Cardiac Diseases. <b>2019</b> , 151-195	О
70	Table olives and health: a review. <b>2020</b> , 9, e57	8
69	Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?. <b>2020</b> , 1, 33-41	1
68	Vitamin E research: Past, now and future. <b>2021</b> , 177, 381-390	6
67	Stable Angina. <b>2020</b> , 83-98	
66	Complementary and Alternative Medicine. <b>2020</b> , 429-446	
65	Diabetic Foot [Research. <b>2020</b> , 173-199	
64	Pathophysiology. <b>2020,</b> 5-22	
63	Oxidative Stress, Lipoproteins and Angiotensin II. <b>2005</b> , 27-37	
62	Synthetic Antioxidants and Atherosclerosis: Human Studies. <b>2006</b> , 255-277	
61	Antioxidant Vitamins and Cardiovascular Disease: Randomized Trials Fail to Fulfill the Promises of Observational Epidemiology. <b>2006</b> , 305-325	
60	Oxidative Stress in the Development of Diabetes and its Complications. <b>2006</b> , 381-397	
59	The Antioxidant Hypothesis. <b>2006</b> , 87-101	
58	Novel Strategies for the Prevention of Vein Graft Failure. <b>2006</b> , 303-310	
57	Vitamine. <b>2005</b> , 342-354	
56	Atherosclerosis. <b>2005,</b> 185-201	
55	Oxidative Stress. <b>2005</b> , 549-562	
54	Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. <b>2006</b> , 113-143	

Observational versus experimental studies: What I the evidence for a hierarchy?. **2004**, 1, 341-347

52	Suppressing or blocking Fis1 reverses diabetic endothelial dysfunction in human resistance arteries.	
51	Tomato lycopene and its role in human health and chronic diseases. <b>2000</b> , 163, 739-44	89
50	Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. <b>2000</b> , 352 Pt 3, 693-9	10
49	Homocysteine: to screen and treat or to wait and see?. <b>2000</b> , 163, 37-8	3
48	Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants. <b>2006</b> , 11, 206-16	34
47	Baseline glutathione peroxidase activity affects prognosis after acute coronary syndromes. <b>2008</b> , 35, 262-7	3
46	Reduction in oxidative stress and modulation of heart failure subsequent to myocardial infarction in rats. <b>2005</b> , 10, 146-53	9
45	Comparison of biomarkers of oxidative stress and cardiovascular disease in humans and chimpanzees (Pan troglodytes). <b>2009</b> , 59, 287-96	16
44	Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine Nitration. <b>2008</b> , 2008, 75	12
43	The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. <b>2010</b> , 2, 316-31	82
42	New paradigms in preventive cardiology: unconventional coronary risk factors. <b>2000</b> , 2, 209-17	O
41	The heart of the matter of opinion and evidence: the value of evidence-based medicine. <b>2012</b> , 12, 57-60	O
40	The care and feeding of evidence based medicine. <b>2012</b> , 71, 97-102	
39	Vitamin E and diabetic nephropathy in mice model and humans. 2013, 2, 111-24	12
38	Model of Traumatic Spinal Cord Injury for Evaluating Pharmacologic Treatments in Cynomolgus Macaques (). <b>2018</b> , 68, 63-73	3
37	Advancements in Free-Radical Pathologies and an Important Treatment Solution with a Free-Radical Inhibitor. <b>2018</b> , 1,	1
36	Interventional study with vitamin E in cardiovascular disease and meta-analysis. <b>2021</b> , 178, 26-41	5

35	Diet-Derived Antioxidants Do Not Decrease Risk of Ischemic Stroke: A Mendelian Randomization Study in 1'Million People. <b>2021</b> , 10, e022567		1
34	Advanced Oxidation Protein Product Promotes Oxidative Accentuation in Renal Epithelial Cells via the Soluble (Pro)renin Receptor-Mediated Intrarenal Renin-Angiotensin System and Nox4-HO Signaling. <b>2021</b> , 2021, 5710440		2
33	Nutrients and Dietary Approaches in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Narrative Review. <b>2021</b> , 13,		1
32	Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <b>2021</b> , 326, 2031-2042		19
31	Change in plasma alpha-tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation <b>2022</b> ,		
30	Mitochondria-targeted drugs for diabetic kidney disease <i>Heliyon</i> , <b>2022</b> , 8, e08878	3.6	3
29	Mitochondria as Therapeutic Targets in Heart Failure Current Heart Failure Reports, 2022, 1	2.8	4
28	Therapeutic enzymes as non-conventional targets in cardiovascular impairments: A Comprehensive Review Canadian Journal of Physiology and Pharmacology, 2021,	2.4	1
27	MicroRNA-210 Controls Mitochondrial Metabolism and Protects Heart Function in Myocardial Infarction <i>Circulation</i> , <b>2022</b> ,	16.7	6
26	Coenzyme Q Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 857364	5.4	1
25	Who is to blame, the chicken or the egg?. Archives of Endocrinology and Metabolism, 2022, 66, 137-138	2.2	
24	Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome. <i>Journal of Cardiovascular Development and Disease</i> , <b>2022</b> , 9, 152	4.2	
23	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease <i>Current Atherosclerosis Reports</i> , <b>2022</b> ,	6	2
22	Antioxidant effects of vitamin E and risk of cardiovascular disease in women with obesity [A narrative review. <i>Clinical Nutrition</i> , <b>2022</b> ,	5.9	2
21	The Modulation of Arachidonic Acid Metabolism and Blood Pressure-Lowering Effect of Honokiol in Spontaneously Hypertensive Rats. <i>Molecules</i> , <b>2022</b> , 27, 3396	4.8	1
20	Antioxidants and cardiovascular diseases. <b>2022</b> , 613-640		
19	Vitamin E 🛭 Von der Entdeckung zu biologischen Funktionen. Ern 🗗 rung & Medizin, <b>2022</b> , 37, 77-82	О	
18	Vasculome. <b>2022,</b> 441-451		

### CITATION REPORT

17	Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference. <i>Briefings in Bioinformatics</i> , <b>2022</b> , 23,	O
16	Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases. <i>Antioxidants</i> , <b>2022</b> , 11, 1408 <sub>7.1</sub>	2
15	Dicarbonyl-Dependent Modification of LDL as a Key Factor of Endothelial Dysfunction and Atherosclerotic Vascular Wall Damage. <b>2022</b> , 11, 1565	О
14	Erythrocyte oxidative stress and thrombosis. 1-26	O
13	Which Studies of Therapy Merit Credence? Vitamin E and Estrogen Therapy as Cautionary Examples. <b>2002</b> , 42, 955-962	1
12	ANTIOXIDANTS IN COMPLEX TREATMENT OF PYOINFLAMMATORY DISEASES IN MAXILLOFACIAL AREA. <b>2010</b> , 27-31	2
11	Inflammation and oxidative stress in salt sensitive hypertension; The role of the NLRP3 inflammasome. 13,	1
10	Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets.	O
9	Berries. <b>2023</b> , 161-217	0
8	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. <b>2023</b> , 137-173	O
7	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. <b>2023</b> , 11, 662	О
6	Oxidative balance score reflects vascular endothelial function of Chinese community dwellers. 14,	O
5	Myocardial Metabolism in Heart Failure. <b>2023</b> , 20, 63-75	О
4	Beneficial and adverse effects of vitamin E on the kidney. 14,	O
3	Associations between vitamin E status and bone mineral density in children and adolescents aged 8🛮 9 years: Evidence based on NHANES 2005 🗷 0006, 2017 🗷 018. <b>2023</b> , 18, e0283127	O
2	The Role of Oxidative Stress Enhanced by Adiposity in Cardiometabolic Diseases. <b>2023</b> , 24, 6382	O
1	Von Real-World-Daten zur Real-World-Evidenz: eine praktische Anleitung.	О